Developmental and Epileptic Encephalopathy 81

Mendelian MONDO:0032858 Pathograph 24 Show in embeddings browser Epilepsy Neurodevelopmental Disorder

Developmental and epileptic encephalopathy 81 (DEE81) is an autosomal recessive, neonatal-onset epileptic encephalopathy caused by biallelic loss-of-function variants in DMXL2. It was delineated in three unrelated families, each with an affected sibling pair, whose phenotype was Ohtahara syndrome - intractable seizures from the first day of life on a suppression-burst EEG background, with profound developmental impairment. Deafness, mild peripheral polyneuropathy and dysmorphic features accompany the epilepsy, so DEE81 is a syndromic rather than an isolated epilepsy. The mechanism is not a channelopathy. DMXL2 encodes rabconnectin-3alpha, a very large scaffold that, together with WDR7 (rabconnectin-3beta) and the linker ROGDI, forms the metazoan RAVE complex - the machine that assembles the V1 and VO halves of the vacuolar H+-ATPase on a membrane. Everything downstream of that assembly step depends on it: lysosomes and endosomes cannot be acidified, synaptic vesicles cannot be loaded with neurotransmitter, and the assembled V-ATPase can no longer recruit ATG16L1 for LC3 conjugation. DEE81 is therefore an encephalopathy of failed organelle acidification, and the patient-level evidence matches: fibroblasts lacking DMXL2 protein show a disturbed endolysosomal compartment and blocked autophagic flux, and the same defect in cultured mouse hippocampal neurons costs them neurite elongation and synapses. The natural history is degenerative as well as developmental. Brain MRI in the first months already shows a thin corpus callosum with hypomyelination, and follow-up imaging shows progressive brain shrinkage with leukoencephalopathy; five of the six patients of the founding cohort died within the first nine years of life, and none acquired any developmental, communicative or motor skill after birth. That combination - a prenatal developmental deficit followed by a progressive course - is what the founding report argues distinguishes this entity. Two things are deliberately left open. First, which arm of the V-ATPase failure actually generates the seizures. The synaptic-vesicle route (failed vesicular acidification, so failed neurotransmitter loading) and the lysosomal-autophagy route (failed degradation, so failed neurite and synapse development, with progressive neuronal loss) are both supported at the level of cell biology, and neither has been shown to be the proximate cause of the epilepsy; the two are curated as competing hypothesis groups rather than as one asserted chain. Second, DMXL2 causes three clinically distinct human phenotypes - this recessive encephalopathy, a dominant non-syndromic deafness (DFNA71), and a polyendocrine-polyneuropathy syndrome - and no published work explains what makes one allele produce one and not another. Only DEE81 sources are cited here.

Ask OpenScientist

Ask a research question about Developmental and Epileptic Encephalopathy 81. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
11
Pathophys.
12
Phenotypes
2
Hypotheses
4
Gaps
24
Pathograph
1
Genes
1
Medical Actions
2
Differentials
3
Models
8
References
1
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC GENETICS ENVIRONMENT DISEASE
🔗

Mappings

MONDO
MONDO:0032858 developmental and epileptic encephalopathy, 81
skos:exactMatch MONDO
MONDO:0032858 is the DEE81 concept, cross-referenced to OMIM:618663 and MEDGEN:1684681, and is the term the curation stub for this disease carried.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
DEE81 is autosomal recessive. Affected individuals carry biallelic DMXL2 loss-of-function alleles, either homozygous or compound heterozygous; the founding cohort was three sibling pairs from three unrelated families, and the one subsequently reported patient was homozygous and born of a consanguineous union.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Using whole exome sequencing, we identified biallelic DMXL2 mutations in three sibling pairs with Ohtahara syndrome, belonging to three unrelated families."
Establishes biallelic DMXL2 variants segregating with the phenotype in three independent families, which is the basis for recessive inheritance.
PMID:40180340 SUPPORT DIRECT Human Clinical
"Through advanced genomic testing, a homozygous nonsense variant in the DMXL2 gene was identified, leading to the diagnosis of DEE81."
An independent, consanguineous case homozygous for a DMXL2 nonsense allele, consistent with autosomal recessive inheritance.
◈

Mechanistic Hypotheses

2
Seizures arise from failed synaptic-vesicle acidification and neurotransmitter loading
synaptic_vesicle_route EMERGING
DMXL2 is enriched in brain and at synaptic terminals, and the V-ATPases that acidify synaptic vesicles - and so drive neurotransmitter loading - depend on rabconnectin-3alpha for assembly. On this model the epilepsy is a synaptic transmission failure, and the lysosomal and autophagic abnormalities are a parallel consequence of the same assembly defect rather than the route to the seizures. It is EMERGING rather than canonical because the proposal is explicitly framed as a suggestion in the source review, and no electrophysiological measurement has been made in a DEE81 neuron.
Distinguishing experiment would be a synaptic-vesicle pH and vesicular neurotransmitter-filling measurement in DEE81 patient-derived neurons, with network excitability recorded in the same preparation.
Pathograph links
Impaired Synaptic Vesicle Loading -> Neuronal Hyperexcitability and Hypersynchrony INDIRECT UNKNOWN INTERMEDIATES Proposed, not demonstrated: if synaptic vesicles cannot be filled, synaptic transmission fails and network activity becomes abnormal. No electrophysiological measurement has been made in a DEE81 neuron, so the intermediates between vesicle-filling failure and hypersynchrony are unknown.
Seizures arise from lysosomal and autophagic failure with defective neurite and synapse development
lysosomal_autophagy_route EMERGING
On this model the proximate lesion is the endolysosomal and autophagic block that is directly demonstrated in patient fibroblasts, and the epilepsy follows from the resulting failure of neurite elongation and synapse formation, which was reproduced in Dmxl2-silenced mouse hippocampal neurons. This is the arm with the most direct experimental support in patient material, but the step from impaired neurite and synapse development to hypersynchronous discharge has not been measured.
The founding report's own conclusion takes this route, but it argues from fibroblast and cultured-neuron data to a clinical syndrome without an intervening excitability measurement.
Pathograph links
Impaired Autophagic Degradation -> Impaired Neurite Elongation and Synapse Formation DIRECT Silencing Dmxl2 in cultured neurons reproduces the lysosomal and autophagic defect and costs those neurons neurite length and synapses.
Impaired Autophagic Degradation -> Progressive Brain Atrophy and Leukoencephalopathy INDIRECT UNKNOWN INTERMEDIATES A sustained block in autophagic degradation is the plausible route to the progressive tissue loss seen on serial imaging, but no study has connected the two directly in this disease, so the intermediates are unstated.
Impaired Neurite Elongation and Synapse Formation -> Neuronal Hyperexcitability and Hypersynchrony INDIRECT UNKNOWN INTERMEDIATES Proposed, not demonstrated: abnormally wired networks with reduced synaptic density are the route to hypersynchronous discharge on this hypothesis. No excitability measurement has been reported in this model or in patient neurons.
?

Discussions and Knowledge Gaps

4
Every mechanistic result in DEE81 comes from a fibroblast or a dissociated neuron culture, and the mouse genotype that matches the patients does not survive to birth. How much of the human disease can the available models actually speak to?
HUMAN MODEL MISMATCH OPEN dee81_no_whole_animal_model
Attached to
animal_models#Mouse experimental_models#Dmxl2-silenced mouse hippocampal neuron culture pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
Complete loss of Dmxl2 is embryonic lethal in mice, so no whole-organism model of the recessive human genotype exists; the viable heterozygote has the wrong zygosity and a phenotype (macrocephaly) the patients do not have. The two systems that do carry the human lesion - patient fibroblasts and Dmxl2-silenced neurons - are both cultures, and neither can produce a seizure, an EEG, myelin, or a progressive atrophy. That is why the edges from the cellular defects to network hyperexcitability are marked INDIRECT_UNKNOWN_INTERMEDIATES: the gap is not that nobody has looked, it is that the systems available cannot look.
Proposed experiments
Conditional or hypomorphic Dmxl2 mouse carrying a human DEE81 allele
dee81_hypomorphic_and_conditional_mouse
Because the constitutive null is embryonic lethal, a viable model needs either a conditional allele deleted after the lethal window or a knock-in of a human DEE81 allele that leaves the residual function compatible with survival. Phenotyping would need EEG, myelination and serial imaging, since those are the features no current model can report.
Would support
pathophysiology#Neuronal Hyperexcitability and Hypersynchrony pathophysiology#Impaired Prenatal Brain Development
Supporting outcome
  • Neonatal-onset seizures with a discontinuous EEG, hypomyelination and progressive volume loss in a viable Dmxl2 mouse would put the human mechanism chain on whole-organism footing.
Refuting outcome
  • A viable Dmxl2 mouse with the cellular lysosomal phenotype but no seizures and normal myelination would argue that the human epilepsy depends on something the mouse does not share, and would move the mismatch from "untested" to "tested and divergent".
Show evidence (1 reference)
PMID:39273013 SUPPORT DIRECT Other
"Complete loss of Dmxl2 is lethal at the embryonic stage in mice"
Establishes that the genotype-matched whole-animal model cannot be made by simple knockout.
Is the milder DMXL2 phenotype - intellectual disability with epilepsy, macrocephaly and dysmorphism, but without neonatal Ohtahara syndrome, deafness or early death - part of DEE81, or a separate allelic disorder?
KNOWLEDGE GAP OPEN dmxl2_phenotypic_expansion
Attached to
genetic#DMXL2 prevalence#Worldwide
A homozygous DMXL2 truncating variant was reported in a child with intellectual disability, epilepsy, macrocephaly and dysmorphism. The reporting group classified it as a phenotype different enough from the published DMXL2 associations to represent a phenotypic expansion or a potentially distinct allelic disorder, and contrasted it explicitly with the endocrine phenotype. A later review counts the same patient as an additional DMXL2 developmental and epileptic encephalopathy case. Both readings are defensible from the published text and they give different answers to how many DEE81 patients exist, which is why the prevalence record here counts only the seven patients described as this disease. Resolving it needs the residual-function question answered: the polyendocrine phenotype is reported with a variant retaining partial transcript, and whether this child's truncating allele leaves residual protein has not been measured.
Show evidence (3 references)
PMID:30237576 SUPPORT DIRECT Human Clinical
"We also found that DMXL2 harbors a homozygous truncating variant"
The primary report of the additional homozygous DMXL2 patient at issue.
PMID:30237576 SUPPORT DIRECT Human Clinical
"although the associated phenotypes are sufficiently different from the original reports that they represent phenotypic expansion or potentially distinct allelic disorders"
The reporting group's own classification of this class of finding, which is what makes the assignment genuinely open rather than settled.
PMID:39273013 SUPPORT DIRECT Other
"An additional homozygous variant in DMXL2 has been reported in a patient with consanguineous parents and presenting DEE and macrocephaly"
The later review counts the same patient as a DMXL2 DEE case, which is the competing reading. Evidence source is OTHER because this is a review.
Which arm of the V-ATPase assembly failure actually generates the seizures in DEE81 - the presynaptic vesicle-filling failure, or the lysosomal and autophagic block with its consequences for neurite and synapse development?
KNOWLEDGE GAP OPEN dee81_seizure_route
Attached to
pathophysiology#Neuronal Hyperexcitability and Hypersynchrony pathophysiology#Impaired Synaptic Vesicle Loading pathophysiology#Impaired Neurite Elongation and Synapse Formation
Both routes are supported at the level of cell biology and neither has been tested against network excitability. The published patient-cell work establishes the lysosomal and autophagic block; the synaptic-vesicle route is stated as a suggestion in a review. No electrophysiological recording has been reported from a DEE81 neuron or from a Dmxl2-deficient network, so the step from either cellular defect to hypersynchronous discharge is unmeasured. This matters therapeutically: the two routes imply different intervention points.
Proposed experiments
Excitability phenotyping of DEE81 patient-derived neurons
dee81_neuron_excitability_phenotyping
Differentiate neurons from DEE81 patient iPSCs and from isogenic corrected controls, plate on multi-electrode arrays, and record spontaneous and evoked network activity alongside vesicular pH, vesicular neurotransmitter content, autophagic flux, neurite length and synapse density in the same cultures. Selective pharmacological or genetic rescue of vesicular acidification versus of autophagic flux would then separate the two routes.
Would support
pathophysiology#Impaired Synaptic Vesicle Loading pathophysiology#Impaired Neurite Elongation and Synapse Formation
Supporting outcome
  • Network hyperexcitability that is corrected by rescuing one arm and not the other identifies that arm as the proximate route to the epilepsy.
Refuting outcome
  • Hyperexcitability that persists when both arms are rescued individually, or absent network hyperexcitability in a genuinely null neuron, would indicate that neither cellular defect is the proximate cause.
Why does DMXL2 produce three clinically distinct human phenotypes - recessive DEE81, dominant non-syndromic deafness DFNA71, and a polyendocrine and polyneuropathy syndrome - and what determines which one a given allele causes?
KNOWLEDGE GAP OPEN dmxl2_allelic_heterogeneity
Attached to
genetic#DMXL2
Distinguishing these entities is a practical curation and diagnostic problem, not only a mechanistic one: a gene-level literature or variant search on DMXL2 returns all three, and their evidence must not be mixed. Zygosity is the obvious axis - DEE81 and the polyendocrine syndrome are biallelic while DFNA71 is heterozygous - but nothing published explains why one biallelic loss-of-function genotype produces a neonatal encephalopathy and another produces an endocrine and peripheral-nerve phenotype, and no allelic series with matched functional measurements exists. Note also that heterozygous DMXL2 deletions occur incidentally in aromatase excess syndrome, where the causal lesion is a neighbouring CYP19A1 rearrangement; those carriers are not reported to have any DMXL2-attributable phenotype.
Show evidence (1 reference)
PMID:34249946 SUPPORT DIRECT Other
"Mutations in DMXL2 have been connected to Ohtahara Syndrome, nonsyndromic hearing loss, and neuroendocrine dysfunction (Tata et al., 2014; Chen et al., 2017; Esposito et al., 2019)."
Establishes that DMXL2 carries three distinct disease associations, which is the premise of this gap. Evidence source is OTHER because this is a review.
⚙

Pathophysiology

11
Biallelic DMXL2 Loss of Function
Biallelic DMXL2 variants - nonsense, splice-site and missense alleles - are the initiating lesion, and they behave as a null: patient fibroblasts contain no detectable DMXL2 protein. This node captures the single concept of the genetic lesion.
DMXL2 hgnc:2938 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased DMXL2 (hgnc:2938). hgnc:2938 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
Downstream
Failed mRAVE-Dependent V-ATPase Assembly Absence of DMXL2 protein removes the rabconnectin-3alpha subunit of the metazoan RAVE complex that assembles the V-ATPase.
Show evidence (2 references)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Siblings in Family 1 were compound heterozygous for the c.5135C>T (p.Ala1712Val) missense substitution and the c.4478C>G (p.Ser1493*) nonsense substitution; in Family 2 were homozygous for the c.4478C>A (p.Ser1493*) nonsense substitution and in Family 3 were homozygous for the c.7518-1G>A..."
Lists the causal biallelic genotypes across the three founding families.
PMID:31688942 SUPPORT DIRECT In Vitro
"Expression analysis in patient-derived skin fibroblasts demonstrated absence of the DMXL2 protein, revealing a loss of function phenotype."
Shows the alleles are functionally null at the protein level in patient cells, which is why this node is modelled as complete loss of function.
Failed mRAVE-Dependent V-ATPase Assembly
DMXL2 (rabconnectin-3alpha) is one of the two alternative large subunits of the metazoan RAVE complex, which also contains WDR7 and the linker ROGDI. mRAVE catalyses the joining of the cytosolic V1 and membrane-embedded VO halves of the vacuolar H+-ATPase after the proton gradient has been dissipated. Without it, the pump cannot be reassembled on demand, and every membrane compartment that depends on regulated V-ATPase assembly loses its acidification capacity. DMXL2 is the brain-enriched paralogue, which is why loss is tolerated elsewhere and not in neurons.
proton-transporting V-ATPase complex assembly GO:0070071 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased proton-transporting V-ATPase complex assembly, annotated with proton-transporting two-sector ATPase complex assembly (GO:0070071). GO:0070071 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Defective Endolysosomal Acidification Without on-demand V1-VO assembly, endosomes and lysosomes cannot maintain their acidic lumen.
Impaired Synaptic Vesicle Loading Vesicular neurotransmitter transporters run on the proton-motive force the V-ATPase generates, so failure to assemble the pump on synaptic vesicles leaves them unfilled.
Show evidence (5 references)
PMID:40646309 SUPPORT DIRECT In Vitro
"mRAVE consists of DMXL1 or DMXL2, WDR7 and the central linker ROGDI."
Identifies DMXL2 as an alternative core subunit of the metazoan RAVE complex, the assembly factor this node is about.
PMID:40646309 SUPPORT DIRECT In Vitro
"mRAVE then catalyzes V1-VO assembly, enabling lysosomal acidification, neurotransmitter loading into vesicles and ATG16L1 recruitment for LC3/ATG8 conjugation onto single membranes."
States the three downstream functions that depend on mRAVE-catalysed assembly, which are the three branches taken from this node.
PMID:31688942 SUPPORT DIRECT Other
"DMXL2 is highly expressed in the brain and at synaptic terminals, regulates v-ATPase assembly and activity and participates in intracellular signalling pathways"
The founding report's own statement of DMXL2's function; evidence source is OTHER because this sentence is the paper's background summary of prior work, not a result of the study.
+ 2 more references
Defective Endolysosomal Acidification
Patient fibroblasts show a disturbed endolysosomal compartment: an increased LysoTracker signal alongside reduced endolysosomal markers and reduced degradative capacity. This node captures the single concept of a dysfunctional, incorrectly acidified endolysosomal system.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
lysosomal lumen acidification GO:0007042 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal lysosomal lumen acidification (GO:0007042). GO:0007042 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Experimental models
DEE81 patient-derived skin fibroblasts PRIMARY CELL CULTURE Cells carrying the patients' own genotype show the endolysosomal abnormality directly.
Downstream
Impaired Autophagic Degradation Autophagic flux terminates in the lysosome, so a compartment that cannot degrade its contents blocks the pathway at its final step.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Patients' fibroblasts also exhibited an increased LysoTracker® signal associated with decreased endolysosomal markers and degradative processes."
Direct measurement of endolysosomal dysfunction in cells from affected individuals.
Impaired Autophagic Degradation
Autophagic flux is blocked: LC3-II falls, polyubiquitinated proteins and the autophagy receptor p62 accumulate, and autolysosomal structures are morphologically abnormal on electron microscopy. This node captures the single concept of failed autophagic degradation.
Seizures arise from lysosomal and autophagic failure with defective neurite and synapse development
autophagy GO:0006914 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased autophagy (GO:0006914). GO:0006914 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
DEE81 patient-derived skin fibroblasts PRIMARY CELL CULTURE The autophagic block is demonstrated in the same patient cells by several independent assays.
Downstream
Impaired Neurite Elongation and Synapse Formation Silencing Dmxl2 in cultured neurons reproduces the lysosomal and autophagic defect and costs those neurons neurite length and synapses. Seizures arise from lysosomal and autophagic failure with defective neurite and synapse development
Progressive Brain Atrophy and Leukoencephalopathy A sustained block in autophagic degradation is the plausible route to the progressive tissue loss seen on serial imaging, but no study has connected the two directly in this disease, so the intermediates are unstated. Seizures arise from lysosomal and autophagic failure with defective neurite and synapse development
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Defective endolysosomal homeostasis was accompanied by impaired autophagy, revealed by lower LC3II signal, accumulation of polyubiquitinated proteins, and autophagy receptor p62, with morphological alterations of the autolysosomal structures on electron microscopy."
Multi-assay demonstration of a block in autophagic flux in patient cells.
Impaired Synaptic Vesicle Loading
Loading of neurotransmitter into a synaptic vesicle is driven by the proton gradient the vesicular V-ATPase generates. Where the pump cannot be assembled, vesicles are not filled. This node captures the single concept of a presynaptic vesicle-filling failure and is the entry point of the synaptic-vesicle hypothesis for the epilepsy.
Seizures arise from failed synaptic-vesicle acidification and neurotransmitter loading
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
synaptic vesicle lumen acidification GO:0097401 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased synaptic vesicle lumen acidification (GO:0097401). GO:0097401 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Neuronal Hyperexcitability and Hypersynchrony Proposed, not demonstrated: if synaptic vesicles cannot be filled, synaptic transmission fails and network activity becomes abnormal. No electrophysiological measurement has been made in a DEE81 neuron, so the intermediates between vesicle-filling failure and hypersynchrony are unknown. Seizures arise from failed synaptic-vesicle acidification and neurotransmitter loading
Show evidence (2 references)
PMID:40646309 SUPPORT INDIRECT Other
"In neurons, the V-ATPase is required to package certain neurotransmitters into synaptic vesicles"
States the dependence of vesicular neurotransmitter packaging on the V-ATPase. Evidence source is OTHER because this sentence is the paper's introductory background rather than its own experiment, and directness is INDIRECT because it is about the pump, not about DMXL2 loss.
PMID:39273013 SUPPORT DIRECT Other
"Rabconnectin-3α interacts with the synaptic vesicle (SV)-associated G-protein Rab3A at the synapse and is strictly involved in the assembly and incorporation of v-ATPase into SVs through its Rav1p domain, homologous to the yeast v-ATPase regulator Rav1p"
Connects DMXL2 specifically to getting the V-ATPase onto synaptic vesicles, which is what makes this node a DMXL2 consequence rather than a general statement about the pump. Evidence source is OTHER because this is a review; one of its authors co-authored the founding DEE81 report.
Impaired Neurite Elongation and Synapse Formation
Neurons in which Dmxl2 is silenced show the same lysosomal and autophagic abnormalities as patient fibroblasts, and in addition fail to elongate their neurites and lose synapses. This node captures the single concept of a neuron-intrinsic failure to build normal processes and connections.
Seizures arise from lysosomal and autophagic failure with defective neurite and synapse development
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
neuron projection morphogenesis GO:0048812 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased neuron projection morphogenesis (GO:0048812). GO:0048812 is a biological process from the Gene Ontology. ↓ DECREASED synapse assembly GO:0007416 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased synapse assembly (GO:0007416). GO:0007416 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
Dmxl2-silenced mouse hippocampal neuron culture PRIMARY CELL CULTURE Silencing Dmxl2 in neurons reproduces the lysosomal and autophagic defect seen in patient cells and adds the neuron-specific consequence: neurites fail to elongate and synapses are lost.
Downstream
Impaired Prenatal Brain Development Neurons that cannot extend processes or form synapses cannot build normal connectivity in the developing brain.
Neuronal Hyperexcitability and Hypersynchrony Proposed, not demonstrated: abnormally wired networks with reduced synaptic density are the route to hypersynchronous discharge on this hypothesis. No excitability measurement has been reported in this model or in patient neurons. Seizures arise from lysosomal and autophagic failure with defective neurite and synapse development
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Altered lysosomal homeostasis and defective autophagy were recapitulated in Dmxl2-silenced mouse hippocampal neurons, which exhibited impaired neurite elongation and synaptic loss."
Reproduces the cellular defect in neurons and adds the neurite and synapse phenotype. Evidence source is IN_VITRO because this is a cultured primary neuron preparation, not a whole animal.
Impaired Prenatal Brain Development
Connectivity fails to reach the expected stage by birth. Imaging in the first months of life already shows a thin corpus callosum and brain hypomyelination in every patient, which is a prenatal rather than a postnatal deficit. This node captures the single concept of an antenatally established structural brain deficit.
Animal models
Dmxl2 heterozygous mouse Mouse partially recapitulates Corpus callosum dysplasia in the heterozygous mouse is the one finding that lines up with the human disease, where a thin corpus callosum is present on the earliest MRI of every patient. It supports the claim that DMXL2 dosage matters for commissural development.
Downstream
Developmental Encephalopathy An antenatally established connectivity deficit is the developmental half of the developmental and epileptic encephalopathy.
Progressive Brain Atrophy and Leukoencephalopathy The same brains that start hypomyelinated go on to shrink, but nothing published establishes whether the progressive loss is a continuation of the developmental lesion or a separate degenerative process.
Thin Corpus Callosum A commissure that failed to form normally is the imaging correlate of the antenatal connectivity deficit.
Cerebral Hypomyelination Deficient myelination on the earliest scans is the other imaging correlate of the same antenatal deficit.
Show evidence (2 references)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all."
Structural evidence, present from the earliest imaging, that brain development was already abnormal before birth.
PMID:31688942 SUPPORT DIRECT Human Clinical
"These clinical findings are consistent with a developmental brain disorder that begins in the prenatal brain, prevents neural connections from reaching the expected stages at birth, and follows a progressive course."
The authors' reading of the combined imaging and clinical data as a prenatal-onset developmental disorder with a progressive course.
Neuronal Hyperexcitability and Hypersynchrony
Populations of neurons fire excessively and synchronously. In DEE81 the signature is electrographic: the founding cohort's phenotype was Ohtahara syndrome, defined by a suppression-burst EEG in which high-amplitude synchronous bursts alternate with near-flat suppression, from the first weeks of life. This node captures the single concept of network hyperexcitability and conforms to the shared epilepsy final common pathway.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
action potential GO:0001508 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased action potential (GO:0001508). GO:0001508 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Neonatal-Onset Refractory Seizures Hypersynchronous network discharge is expressed clinically as seizures.
EEG with Burst Suppression Bursts of synchronous high-amplitude activity alternating with near-flat suppression are the electrographic expression of this network state.
Show evidence (1 reference)
PMID:31688942 SUPPORT INDIRECT Other
"Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability."
Defines the electroclinical syndrome these patients were shown to have; the suppression-burst pattern is the network-level signature of hypersynchronous discharge. Evidence source is OTHER and directness INDIRECT because this sentence defines Ohtahara syndrome generally rather than reporting a DEE81 measurement.
Neonatal-Onset Refractory Seizures
The clinical endpoint of the epileptic arm: recurrent seizures beginning in the first day or days of life that do not respond to antiseizure medication. This node captures the single concept of the drug-resistant seizure state and conforms to the shared epilepsy final common pathway.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Seizure This node is the mechanism-side statement of the clinical seizure phenotype.
Focal-Onset Seizure Focal onset is the semiology recorded in the one patient described outside the founding cohort.
Epileptic Encephalopathy Refractory seizures from the first day of life, together with the developmental impairment, constitute the epileptic encephalopathy.
Developmental Encephalopathy Continuous early-life epileptic activity is conventionally held to worsen development, and it is the epileptic half of the name, but in DEE81 the developmental deficit is already present at birth and no study separates the seizure-driven contribution from the antenatal one.
Show evidence (2 references)
PMID:31688942 SUPPORT DIRECT Human Clinical
"The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
Dates onset to the first day of life and names the accompanying syndromic features.
PMID:40180340 SUPPORT DIRECT Human Clinical
"Despite initial treatment with multiple antiepileptics, seizures persisted, prompting a thorough diagnostic evaluation."
Documents drug resistance in an independently reported DEE81 neonate.
Developmental Encephalopathy
Profound, non-progressing-forward developmental impairment: patients acquired no developmental, communicative or motor skill after birth. Both the antenatal connectivity deficit and the neonatal-onset epilepsy converge here. This node captures the single concept of the developmental half of the syndrome.
Downstream
Profound Global Developmental Delay The clinical measure of this node is the complete absence of developmental attainment.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth."
Records the absence of any developmental attainment across the founding cohort.
Progressive Brain Atrophy and Leukoencephalopathy
Serial imaging shows the brain losing volume, with white-matter disease, over follow-up - a degenerative course superimposed on the developmental deficit. This node captures the single concept of progressive structural brain loss and is what distinguishes DEE81 from a static encephalopathy.
Downstream
Cerebral Atrophy Progressive volume loss is reported on serial MRI as brain shrinkage.
Leukoencephalopathy White-matter disease accompanies the volume loss on the same scans.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
Serial imaging in three of the six patients documents progressive volume loss with white-matter change.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Developmental and Epileptic Encephalopathy 81 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Ear 1
Hearing Impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Deafness, annotated with Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Bound to HP:0000365 Hearing impairment rather than to the sensorineural child term, because the source says only "deafness". Narrowing it to sensorineural would have to be argued from the DFNA71 hair-cell literature, which this entry deliberately does not cite for DEE81 claims; taking the binding from a source about a different disease is the error the narrower term would encode. If a DEE81 report gives audiological detail, the term can be specialised then.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
Names deafness as an accompanying feature of the syndrome.
Head and Neck 1
Abnormal Facial Shape HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysmorphic features, annotated with Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
Names dysmorphic features as an accompanying finding.
Nervous System 10
Epileptic Encephalopathy HP:0200134 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Epileptic encephalopathy (HP:0200134), qualified as neonatal onset. HP:0200134 is a phenotype from the Human Phenotype Ontology.
Onset: NEONATAL
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
States the epileptic encephalopathy and its first-day-of-life onset.
Seizure OBLIGATE HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250), qualified as neonatal onset. HP:0001250 is a phenotype from the Human Phenotype Ontology.
Onset: NEONATAL
OBLIGATE rests on all seven reported patients having seizures - the six of the founding cohort, whose electroclinical diagnosis was Ohtahara syndrome, and the one later neonate. Seizures are also definitional for a developmental and epileptic encephalopathy, so the denominator is small but the claim is not in doubt.
Show evidence (2 references)
PMID:40180340 SUPPORT DIRECT Human Clinical
"Here, we report the case of a neonate born from a consanguineous marriage, presenting with refractory focal seizures shortly after birth."
An independently reported DEE81 patient with refractory seizures from shortly after birth.
PMID:31688942 SUPPORT DIRECT Human Clinical
"The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
Covers the six patients of the founding cohort, all of whom had the epileptic encephalopathy from the first day of life.
Focal-Onset Seizure HP:0007359 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Focal-onset seizure (HP:0007359). HP:0007359 is a phenotype from the Human Phenotype Ontology.
Recorded from a single case. The founding cohort is described at the level of the Ohtahara electroclinical syndrome rather than by individual semiology, so no frequency is asserted.
Show evidence (1 reference)
PMID:40180340 SUPPORT DIRECT Human Clinical
"Here, we report the case of a neonate born from a consanguineous marriage, presenting with refractory focal seizures shortly after birth."
Names the seizure onset as focal in this patient.
EEG with Burst Suppression HP:0010851 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is EEG with burst suppression (HP:0010851). HP:0010851 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31688942 SUPPORT INDIRECT Other
"Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability."
Defines suppression-burst as the EEG pattern of Ohtahara syndrome, which is the diagnosis these patients were given. Directness is INDIRECT and the source is OTHER because this sentence defines the syndrome rather than reporting these patients' recordings.
Profound Global Developmental Delay OBLIGATE HP:0012736 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Profound global developmental delay (HP:0012736). HP:0012736 is a phenotype from the Human Phenotype Ontology.
The denominator for OBLIGATE is the six patients of the founding cohort, in all of whom no skill was acquired. The one later-reported patient was a neonate at the time of publication, so no developmental outcome is available.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth."
Absence of any skill acquisition in all six patients is the profound end of the developmental-delay scale.
Peripheral Neuropathy HP:0009830 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Peripheral neuropathy (HP:0009830), qualified as severity mild. HP:0009830 is a phenotype from the Human Phenotype Ontology.
Severity: MILD
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
Names a mild peripheral polyneuropathy as an accompanying feature.
Thin Corpus Callosum OBLIGATE HP:0033725 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thin corpus callosum (HP:0033725). HP:0033725 is a phenotype from the Human Phenotype Ontology.
"In all" in the source means all six patients of the founding cohort, which is the denominator behind OBLIGATE here.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all."
Reports a thin corpus callosum in all patients on early imaging.
Cerebral Hypomyelination OBLIGATE HP:0006808 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral hypomyelination (HP:0006808). HP:0006808 is a phenotype from the Human Phenotype Ontology.
As for the thin corpus callosum, "in all" is all six patients of the founding cohort.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all."
Reports brain hypomyelination in all patients on early imaging.
Cerebral Atrophy HP:0002059 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral atrophy (HP:0002059), qualified as course progressive. HP:0002059 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
The denominator is the three patients who had follow-up scans, not the whole cohort, so no frequency is asserted.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
Documents progressive brain volume loss on serial imaging.
Leukoencephalopathy HP:0002352 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Leukoencephalopathy (HP:0002352), qualified as course progressive. HP:0002352 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
As for cerebral atrophy, the denominator is the three patients with serial scans.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
Reports leukoencephalopathy on follow-up imaging.
🧬

Genetic Associations

1
DMXL2 (Causative)
Gene: DMXL2 hgnc:2938 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is DMXL2 (hgnc:2938). hgnc:2938 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Siblings in Family 1 were compound heterozygous for the c.5135C>T (p.Ala1712Val) missense substitution and the c.4478C>G (p.Ser1493*) nonsense substitution; in Family 2 were homozygous for the c.4478C>A (p.Ser1493*) nonsense substitution and in Family 3 were homozygous for the c.7518-1G>A..."
The causal genotypes reported across the three founding families.
PMID:34249946 SUPPORT INDIRECT Other
"DMXL2 (Rabconnectin-3α) and WDR7 (Rabconnectin-3β) together comprise a synaptic Rabconnectin-3 complex in an apparent 1:1 ratio (Kawabe et al., 2003)."
Identifies the gene product as rabconnectin-3alpha and its obligate partner. Evidence source is OTHER because this is a review.
💊

Medical Actions

1
Antiseizure Medication
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Small molecule
Multiple antiseizure medications were used in the one DEE81 patient whose treatment course is described, and seizures persisted. No disease-modifying therapy exists, and no antiseizure agent has been reported to control seizures in this disorder.
Show evidence (1 reference)
PMID:40180340 SUPPORT DIRECT Human Clinical
"Despite initial treatment with multiple antiepileptics, seizures persisted, prompting a thorough diagnostic evaluation."
Documents that multiple antiseizure medications were given and did not control the seizures.
🔬

Diagnosis

3
Molecular Genetic Testing
The diagnosis is molecular: identification of biallelic pathogenic DMXL2 variants in a neonate with early-onset refractory seizures. Both published reports reached DEE81 that way - the founding cohort by whole exome sequencing, the later case by targeted genomic testing - and there is no biochemical marker to screen for.
Genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:40180340 SUPPORT DIRECT Human Clinical
"This case underscores the importance of considering genetic aetiologies in neonates with early-onset seizures and highlights the value of targeted genetic analysis in guiding personalised management strategies."
States the diagnostic role of genetic testing in a neonate with early-onset seizures.
PMID:31688942 SUPPORT DIRECT Human Clinical
"Using whole exome sequencing, we identified biallelic DMXL2 mutations in three sibling pairs with Ohtahara syndrome, belonging to three unrelated families."
Exome sequencing is how the founding cohort was diagnosed.
Brain MRI
Imaging supports the diagnosis rather than making it, but it is informative in both directions. Unlike many DEEs, early MRI in DEE81 is not normal: a thin corpus callosum with hypomyelination was present in every patient in the first months of life, and repeat imaging shows progressive shrinkage with leukoencephalopathy. A normal early scan would therefore argue against DEE81.
Show evidence (2 references)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all."
Early MRI is abnormal in every patient, which is what gives it diagnostic value here.
PMID:31688942 SUPPORT DIRECT Human Clinical
"Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
Repeat imaging adds the progressive component, which distinguishes DEE81 from a static encephalopathy.
Electroencephalography
EEG establishes the electroclinical syndrome. Every patient of the founding cohort was diagnosed with Ohtahara syndrome, which is defined by a suppression-burst pattern in the first weeks of life.
Show evidence (1 reference)
PMID:31688942 SUPPORT INDIRECT Other
"Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability."
Defines the EEG pattern that identifies the electroclinical syndrome these patients were given. Evidence source is OTHER and directness INDIRECT because this sentence defines Ohtahara syndrome rather than reporting these patients' recordings.
📈

Progression

4
Neonatal presentation
Age: First day of life
Seizures begin on the first day of life, on a suppression-burst EEG background, and are refractory to multiple antiseizure medications from the outset.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
Dates the onset of the encephalopathy to the first day of life.
Developmental arrest from birth
Milestones are not merely delayed: no patient of the founding cohort acquired any developmental, communicative or motor skill after birth. The structural correlate is already visible on the first MRI, as a thin corpus callosum with hypomyelination.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth."
Records that no skill was acquired at any point after birth.
Progressive neurodegenerative course
On follow-up imaging the brain shrinks and develops leukoencephalopathy, so the course is degenerative as well as developmental. This is the feature the founding report treats as distinguishing.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
Serial imaging showing progressive structural loss.
Death in childhood
Age: Within the first 9 years of life
Five of the six patients of the founding cohort died within the first nine years of life. Fatal outcome is recorded here rather than as a phenotype because HPO files death in infancy and childhood under clinical course rather than under phenotypic abnormality.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth."
Reports mortality in five of the six patients within the first nine years.
📊

Prevalence

1
Worldwide
Cases In Literature Not yet documented
Seven patients are reported as this disease: six from the three founding families, and one later consanguineous neonate. An eighth homozygous DMXL2 patient exists in the literature but is counted here as unresolved rather than as a DEE81 case - see the dmxl2_phenotypic_expansion discussion, where the primary report and a later review disagree about whether that phenotype belongs to this entity. No population rate has been estimated, so no numeric prevalence is asserted.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Human Clinical
"Using whole exome sequencing, we identified biallelic DMXL2 mutations in three sibling pairs with Ohtahara syndrome, belonging to three unrelated families."
Accounts for six of the seven reported patients.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Developmental and Epileptic Encephalopathy 81:

Other genetic causes of Ohtahara syndrome
Overlapping Features Ohtahara syndrome is an electroclinical diagnosis, not an aetiology: the same neonatal suppression-burst picture is produced by variants in many different genes, so identifying Ohtahara syndrome does not identify DEE81. The founding report says exactly this, which is why the cohort needed exome sequencing to be resolved.
Distinguishing Features
  • Three features separate DEE81 from a typical channelopathy or synaptopathy Ohtahara syndrome. It is syndromic - deafness, mild peripheral polyneuropathy and dysmorphic features accompany the epilepsy. Its early MRI is abnormal, with a thin corpus callosum and hypomyelination in every patient, where many other Ohtahara aetiologies have normal early imaging. And it is progressive, with brain shrinkage and leukoencephalopathy on follow-up scans. Inheritance is recessive, so an affected sibling pair is expected and a de novo variant is not.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT Other
"Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability."
States the aetiological heterogeneity that makes the electroclinical diagnosis insufficient on its own. Evidence source is OTHER because this sentence is the paper's background definition.
STXBP1 encephalopathy MONDO:0012812
Overlapping Features The best-characterised single-gene cause of Ohtahara syndrome, and the one a neonate with refractory seizures on a suppression-burst EEG is most likely to be tested for. About a fifth of STXBP1 patients present as Ohtahara syndrome.
Distinguishing Features
  • Zygosity is the cleanest discriminator. STXBP1 encephalopathy is caused by heterozygous variants acting through haploinsufficiency, so it is dominant and typically de novo; DEE81 is recessive, and in the founding cohort every family had two affected siblings. A recurrence in siblings therefore argues for DEE81 and against STXBP1.
  • The DEE81-specific findings are the positive discriminators: deafness, mild peripheral polyneuropathy and dysmorphic features accompanying the epilepsy, a thin corpus callosum with hypomyelination on the earliest MRI, and progressive brain shrinkage with leukoencephalopathy on follow-up. These are stated from the DEE81 side; this entry does not assert what STXBP1 imaging or extraneural features look like, because its sources do not cover that.
Show evidence (3 references)
PMID:18469812 SUPPORT DIRECT Human Clinical
"Early infantile epileptic encephalopathy with suppression-burst (EIEE), also known as Ohtahara syndrome, is one of the most severe and earliest forms of epilepsy."
Anchors STXBP1 to the same Ohtahara/suppression-burst presentation DEE81 produces.
PMID:26865513 SUPPORT DIRECT Human Clinical
"While one-third of patients presented with Ohtahara syndrome (21%) or West syndrome (9.5%), the majority has a nonsyndromic early-onset epilepsy and encephalopathy (53%) with epileptic spasms or tonic seizures as main seizure type."
Quantifies how often STXBP1 presents as Ohtahara syndrome, which is what makes it the leading differential.
PMID:18469812 SUPPORT DIRECT Human Clinical
"These findings suggest that haploinsufficiency of STXBP1 causes EIEE."
Establishes the dominant, haploinsufficiency mechanism, which is the discriminator against recessive DEE81.
🧫

Experimental Models

2
DEE81 patient-derived skin fibroblasts PRIMARY_CELL_CULTURE
Primary dermal fibroblasts from affected individuals, which contain no detectable DMXL2 protein and reproduce the endolysosomal and autophagic defect. The most direct human model of the cellular lesion, but a non-neuronal one.
Publication
PMID:31688942
Pathograph links
Defective Endolysosomal Acidification recapitulates fidelity: high Cells carrying the patients' own genotype show the endolysosomal abnormality directly.
Limitations: Fibroblasts are not neurons and express the ubiquitous DMXL1 paralogue, so the magnitude of the defect in a fibroblast is not a guide to its magnitude in a brain-enriched, DMXL2-dependent cell.
Readouts
LysoTracker signal and endolysosomal marker abundance
Direction: ALTERED
Interpretation: Increased LysoTracker signal with reduced endolysosomal markers and reduced degradative capacity is the measured correlate of this node.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Patients' fibroblasts also exhibited an increased LysoTracker® signal associated with decreased endolysosomal markers and degradative processes."
The measurement itself, made in patient fibroblasts.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Expression analysis in patient-derived skin fibroblasts demonstrated absence of the DMXL2 protein, revealing a loss of function phenotype."
Establishes that these cells are a genuine null model of the patients' lesion, which is why they are informative for this node.
Impaired Autophagic Degradation recapitulates fidelity: high The autophagic block is demonstrated in the same patient cells by several independent assays.
Limitations: Autophagic flux was assessed in a dividing, non-neuronal cell type; neurons are post-mitotic and far more dependent on basal autophagy, so the consequences of the same block are not necessarily comparable.
Readouts
LC3-II, p62 and polyubiquitinated protein levels
Direction: ALTERED
Interpretation: Lower LC3-II with accumulation of p62 and polyubiquitinated proteins, plus abnormal autolysosomal ultrastructure, is the measured correlate of a blocked autophagic pathway.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Defective endolysosomal homeostasis was accompanied by impaired autophagy, revealed by lower LC3II signal, accumulation of polyubiquitinated proteins, and autophagy receptor p62, with morphological alterations of the autolysosomal structures on electron microscopy."
The multi-assay measurement of the autophagic block.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Expression analysis in patient-derived skin fibroblasts demonstrated absence of the DMXL2 protein, revealing a loss of function phenotype."
The cells are protein-null for DMXL2, so an autophagic defect measured in them is attributable to the disease lesion.
Dmxl2-silenced mouse hippocampal neuron culture PRIMARY_CELL_CULTURE
Cultured primary mouse hippocampal neurons in which Dmxl2 is knocked down. The only neuronal model reported for this disease, and the only place the neurite and synapse phenotype has been observed.
Publication
PMID:31688942
Pathograph links
Impaired Neurite Elongation and Synapse Formation recapitulates fidelity: moderate Silencing Dmxl2 in neurons reproduces the lysosomal and autophagic defect seen in patient cells and adds the neuron-specific consequence: neurites fail to elongate and synapses are lost.
Limitations: This is acute RNA-interference knockdown in mouse neurons, not a constitutive biallelic human null, so residual protein and off-target effects are not excluded; and it is a dissociated culture, which cannot report the network-level excitability that would connect this node to the seizures.
Readouts
Neurite length and synapse number
Direction: DECREASED
Interpretation: Reduced neurite elongation and synaptic loss are the measured correlates of this node.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Altered lysosomal homeostasis and defective autophagy were recapitulated in Dmxl2-silenced mouse hippocampal neurons, which exhibited impaired neurite elongation and synaptic loss."
The measurement of neurite and synapse loss in Dmxl2-silenced neurons.
Show evidence (1 reference)
PMID:31688942 SUPPORT DIRECT In Vitro
"Altered lysosomal homeostasis and defective autophagy were recapitulated in Dmxl2-silenced mouse hippocampal neurons, which exhibited impaired neurite elongation and synaptic loss."
The same sentence establishes that the model reproduces the patient-cell defect, which is what makes it informative for this node.
🐁

Animal Models

1
Dmxl2 heterozygous mouse
The only viable mouse genotype available for this gene. Complete loss of Dmxl2 is embryonic lethal in mice, so the genotype that matches the patients - biallelic null - cannot be studied in a whole animal. Heterozygous mice are viable and show macrocephaly and corpus callosum dysplasia.
Species
Mouse
Genotype
Dmxl2 heterozygous null
Genes
DMXL2 hgnc:2938 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns DMXL2 (hgnc:2938). hgnc:2938 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:39273013
Pathograph links
Impaired Prenatal Brain Development partially recapitulates fidelity: low Corpus callosum dysplasia in the heterozygous mouse is the one finding that lines up with the human disease, where a thin corpus callosum is present on the earliest MRI of every patient. It supports the claim that DMXL2 dosage matters for commissural development.
Limitations: The zygosity is wrong. DEE81 is recessive and the heterozygous carriers in all three founding families were clinically unaffected, so a mouse that is abnormal at half dosage is not modelling the human carrier state either. The mouse also has macrocephaly, which the founding cohort does not, and none of the defining features of the disease - neonatal seizures, suppression-burst EEG, deafness, progressive atrophy - is reported in it. The matched homozygous null is embryonic lethal, so the fidelity of this model to the human recessive disease is low by construction rather than by measurement.
Readouts
Corpus callosum morphology
Direction: ALTERED
Interpretation: Callosal dysplasia at half Dmxl2 dosage is the murine counterpart of the thin corpus callosum seen on early human MRI.
Show evidence (1 reference)
PMID:39273013 SUPPORT DIRECT Other
"heterozygous DMXL2 mice show macrocephaly and corpus callosum dysplasia"
The reported callosal and head-size findings in the heterozygous mouse.
Show evidence (1 reference)
PMID:39273013 SUPPORT INDIRECT Other
"uncovering the relevance of early v-ATPase regulation in brain development and function"
The review's own reading of why the mouse dosage phenotype is informative for brain development, which is the claim that makes this model relevant to this node. Directness is INDIRECT because it is a general statement about v-ATPase regulation rather than about DEE81.
Show evidence (1 reference)
PMID:39273013 SUPPORT DIRECT Other
"Complete loss of Dmxl2 is lethal at the embryonic stage in mice"
The homozygous null, which is the genotype matching the patients, does not survive to birth in mice - which is why the heterozygote is the only viable mouse. Evidence source is OTHER because this is a review reporting other groups' mouse work rather than an original animal study.
{ }

Source YAML

click to show 
name: Developmental and Epileptic Encephalopathy 81
creation_date: "2026-09-02T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: developmental and epileptic encephalopathy, 81
  term:
    id: MONDO:0032858
    label: developmental and epileptic encephalopathy, 81
synonyms:
- DEE81
- DEE 81
- EIEE81
- Epileptic encephalopathy, early infantile, 81
- DMXL2-related Ohtahara syndrome
description: >-
  Developmental and epileptic encephalopathy 81 (DEE81) is an autosomal recessive,
  neonatal-onset epileptic encephalopathy caused by biallelic loss-of-function
  variants in DMXL2. It was delineated in three unrelated families, each with an
  affected sibling pair, whose phenotype was Ohtahara syndrome - intractable
  seizures from the first day of life on a suppression-burst EEG background, with
  profound developmental impairment. Deafness, mild peripheral polyneuropathy and
  dysmorphic features accompany the epilepsy, so DEE81 is a syndromic rather than
  an isolated epilepsy.

  The mechanism is not a channelopathy. DMXL2 encodes rabconnectin-3alpha, a very
  large scaffold that, together with WDR7 (rabconnectin-3beta) and the linker
  ROGDI, forms the metazoan RAVE complex - the machine that assembles the V1 and
  VO halves of the vacuolar H+-ATPase on a membrane. Everything downstream of that
  assembly step depends on it: lysosomes and endosomes cannot be acidified,
  synaptic vesicles cannot be loaded with neurotransmitter, and the assembled
  V-ATPase can no longer recruit ATG16L1 for LC3 conjugation. DEE81 is therefore
  an encephalopathy of failed organelle acidification, and the patient-level
  evidence matches: fibroblasts lacking DMXL2 protein show a disturbed
  endolysosomal compartment and blocked autophagic flux, and the same defect in
  cultured mouse hippocampal neurons costs them neurite elongation and synapses.

  The natural history is degenerative as well as developmental. Brain MRI in the
  first months already shows a thin corpus callosum with hypomyelination, and
  follow-up imaging shows progressive brain shrinkage with leukoencephalopathy;
  five of the six patients of the founding cohort died within the first nine years
  of life, and none acquired any developmental, communicative or motor skill after
  birth. That combination - a prenatal developmental deficit followed by a
  progressive course - is what the founding report argues distinguishes this
  entity.

  Two things are deliberately left open. First, which arm of the V-ATPase failure
  actually generates the seizures. The synaptic-vesicle route (failed vesicular
  acidification, so failed neurotransmitter loading) and the lysosomal-autophagy
  route (failed degradation, so failed neurite and synapse development, with
  progressive neuronal loss) are both supported at the level of cell biology, and
  neither has been shown to be the proximate cause of the epilepsy; the two are
  curated as competing hypothesis groups rather than as one asserted chain.
  Second, DMXL2 causes three clinically distinct human phenotypes - this recessive
  encephalopathy, a dominant non-syndromic deafness (DFNA71), and a
  polyendocrine-polyneuropathy syndrome - and no published work explains what
  makes one allele produce one and not another. Only DEE81 sources are cited here.
parents:
- Epilepsy
- Neurodevelopmental Disorder
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:31688942
      reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
      explanation: "A seizure and neurodevelopmental disorder of the central nervous system, with peripheral-nerve involvement."
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:31688942
      reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "Using whole exome sequencing, we identified biallelic DMXL2 mutations in three sibling pairs with Ohtahara syndrome, belonging to three unrelated families."
      explanation: "A single-gene recessive disorder, established by exome sequencing in three independent families."
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0032858
      label: developmental and epileptic encephalopathy, 81
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0032858 is the DEE81 concept, cross-referenced to OMIM:618663 and
      MEDGEN:1684681, and is the term the curation stub for this disease carried.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    DEE81 is autosomal recessive. Affected individuals carry biallelic DMXL2
    loss-of-function alleles, either homozygous or compound heterozygous; the
    founding cohort was three sibling pairs from three unrelated families, and the
    one subsequently reported patient was homozygous and born of a consanguineous
    union.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using whole exome sequencing, we identified biallelic DMXL2 mutations in three sibling pairs with Ohtahara syndrome, belonging to three unrelated families."
    explanation: "Establishes biallelic DMXL2 variants segregating with the phenotype in three independent families, which is the basis for recessive inheritance."
  - reference: PMID:40180340
    reference_title: "Neonate with developmental and epileptic encephalopathy 81 (DEE81): lessons learnt and future implications."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Through advanced genomic testing, a homozygous nonsense variant in the DMXL2 gene was identified, leading to the diagnosis of DEE81."
    explanation: "An independent, consanguineous case homozygous for a DMXL2 nonsense allele, consistent with autosomal recessive inheritance."
mechanistic_hypotheses:
- hypothesis_group_id: synaptic_vesicle_route
  hypothesis_label: Seizures arise from failed synaptic-vesicle acidification and neurotransmitter loading
  status: EMERGING
  description: >-
    DMXL2 is enriched in brain and at synaptic terminals, and the V-ATPases that
    acidify synaptic vesicles - and so drive neurotransmitter loading - depend on
    rabconnectin-3alpha for assembly. On this model the epilepsy is a synaptic
    transmission failure, and the lysosomal and autophagic abnormalities are a
    parallel consequence of the same assembly defect rather than the route to the
    seizures. It is EMERGING rather than canonical because the proposal is
    explicitly framed as a suggestion in the source review, and no
    electrophysiological measurement has been made in a DEE81 neuron.
  notes: >-
    Distinguishing experiment would be a synaptic-vesicle pH and vesicular
    neurotransmitter-filling measurement in DEE81 patient-derived neurons, with
    network excitability recorded in the same preparation.
- hypothesis_group_id: lysosomal_autophagy_route
  hypothesis_label: Seizures arise from lysosomal and autophagic failure with defective neurite and synapse development
  status: EMERGING
  description: >-
    On this model the proximate lesion is the endolysosomal and autophagic block
    that is directly demonstrated in patient fibroblasts, and the epilepsy follows
    from the resulting failure of neurite elongation and synapse formation, which
    was reproduced in Dmxl2-silenced mouse hippocampal neurons. This is the arm
    with the most direct experimental support in patient material, but the step
    from impaired neurite and synapse development to hypersynchronous discharge
    has not been measured.
  notes: >-
    The founding report's own conclusion takes this route, but it argues from
    fibroblast and cultured-neuron data to a clinical syndrome without an
    intervening excitability measurement.
pathophysiology:
- name: Biallelic DMXL2 Loss of Function
  description: >-
    Biallelic DMXL2 variants - nonsense, splice-site and missense alleles - are the
    initiating lesion, and they behave as a null: patient fibroblasts contain no
    detectable DMXL2 protein. This node captures the single concept of the genetic
    lesion.
  role: trigger
  biological_scale: MOLECULAR
  gene:
    preferred_term: DMXL2
    modifier: DECREASED
    term:
      id: hgnc:2938
      label: DMXL2
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Siblings in Family 1 were compound heterozygous for the c.5135C>T (p.Ala1712Val) missense substitution and the c.4478C>G (p.Ser1493*) nonsense substitution; in Family 2 were homozygous for the c.4478C>A (p.Ser1493*) nonsense substitution and in Family 3 were homozygous for the c.7518-1G>A (p.Trp2507Argfs*4) substitution."
    explanation: "Lists the causal biallelic genotypes across the three founding families."
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    snippet: "Expression analysis in patient-derived skin fibroblasts demonstrated absence of the DMXL2 protein, revealing a loss of function phenotype."
    explanation: "Shows the alleles are functionally null at the protein level in patient cells, which is why this node is modelled as complete loss of function."
  downstream:
  - target: Failed mRAVE-Dependent V-ATPase Assembly
    causal_link_type: DIRECT
    description: >-
      Absence of DMXL2 protein removes the rabconnectin-3alpha subunit of the
      metazoan RAVE complex that assembles the V-ATPase.
- name: Failed mRAVE-Dependent V-ATPase Assembly
  description: >-
    DMXL2 (rabconnectin-3alpha) is one of the two alternative large subunits of the
    metazoan RAVE complex, which also contains WDR7 and the linker ROGDI. mRAVE
    catalyses the joining of the cytosolic V1 and membrane-embedded VO halves of
    the vacuolar H+-ATPase after the proton gradient has been dissipated. Without
    it, the pump cannot be reassembled on demand, and every membrane compartment
    that depends on regulated V-ATPase assembly loses its acidification capacity.
    DMXL2 is the brain-enriched paralogue, which is why loss is tolerated
    elsewhere and not in neurons.
  role: mediator
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: proton-transporting V-ATPase complex assembly
    modifier: DECREASED
    term:
      id: GO:0070071
      label: proton-transporting two-sector ATPase complex assembly
  evidence:
  - reference: PMID:40646309
    reference_title: "A heterotrimeric protein complex assembles the metazoan V-ATPase upon dissipation of proton gradients."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    snippet: "mRAVE consists of DMXL1 or DMXL2, WDR7 and the central linker ROGDI."
    explanation: "Identifies DMXL2 as an alternative core subunit of the metazoan RAVE complex, the assembly factor this node is about."
  - reference: PMID:40646309
    reference_title: "A heterotrimeric protein complex assembles the metazoan V-ATPase upon dissipation of proton gradients."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    snippet: "mRAVE then catalyzes V1-VO assembly, enabling lysosomal acidification, neurotransmitter loading into vesicles and ATG16L1 recruitment for LC3/ATG8 conjugation onto single membranes."
    explanation: "States the three downstream functions that depend on mRAVE-catalysed assembly, which are the three branches taken from this node."
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "DMXL2 is highly expressed in the brain and at synaptic terminals, regulates v-ATPase assembly and activity and participates in intracellular signalling pathways"
    explanation: "The founding report's own statement of DMXL2's function; evidence source is OTHER because this sentence is the paper's background summary of prior work, not a result of the study."
  - reference: PMID:34249946
    reference_title: "RAVE and Rabconnectin-3 Complexes as Signal Dependent Regulators of Organelle Acidification."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "DMXL2 expression is highly enriched in brain, although it is also expressed in other tissues."
    explanation: "Explains why loss of the DMXL2 paralogue produces a brain-predominant phenotype while the ubiquitous DMXL1 paralogue continues to serve other tissues. Evidence source is OTHER because this is a review."
  - reference: PMID:39273013
    reference_title: "V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "The DMXL2 gene encodes for rabconnectin-3α, a member of the WD40 repeat (WDR) protein family that is highly expressed in the brain."
    explanation: "Independent statement of the gene product's identity and its brain enrichment. Evidence source is OTHER because this is a review."
  downstream:
  - target: Defective Endolysosomal Acidification
    causal_link_type: DIRECT
    description: >-
      Without on-demand V1-VO assembly, endosomes and lysosomes cannot maintain
      their acidic lumen.
  - target: Impaired Synaptic Vesicle Loading
    causal_link_type: DIRECT
    description: >-
      Vesicular neurotransmitter transporters run on the proton-motive force the
      V-ATPase generates, so failure to assemble the pump on synaptic vesicles
      leaves them unfilled.
- name: Defective Endolysosomal Acidification
  description: >-
    Patient fibroblasts show a disturbed endolysosomal compartment: an increased
    LysoTracker signal alongside reduced endolysosomal markers and reduced
    degradative capacity. This node captures the single concept of a
    dysfunctional, incorrectly acidified endolysosomal system.
  role: mediator
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: lysosomal lumen acidification
    modifier: ABNORMAL
    term:
      id: GO:0007042
      label: lysosomal lumen acidification
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    snippet: "Patients' fibroblasts also exhibited an increased LysoTracker® signal associated with decreased endolysosomal markers and degradative processes."
    explanation: "Direct measurement of endolysosomal dysfunction in cells from affected individuals."
  downstream:
  - target: Impaired Autophagic Degradation
    causal_link_type: DIRECT
    description: >-
      Autophagic flux terminates in the lysosome, so a compartment that cannot
      degrade its contents blocks the pathway at its final step.
- name: Impaired Autophagic Degradation
  description: >-
    Autophagic flux is blocked: LC3-II falls, polyubiquitinated proteins and the
    autophagy receptor p62 accumulate, and autolysosomal structures are
    morphologically abnormal on electron microscopy. This node captures the single
    concept of failed autophagic degradation.
  role: mediator
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: autophagy
    modifier: DECREASED
    term:
      id: GO:0006914
      label: autophagy
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    snippet: "Defective endolysosomal homeostasis was accompanied by impaired autophagy, revealed by lower LC3II signal, accumulation of polyubiquitinated proteins, and autophagy receptor p62, with morphological alterations of the autolysosomal structures on electron microscopy."
    explanation: "Multi-assay demonstration of a block in autophagic flux in patient cells."
  downstream:
  - target: Impaired Neurite Elongation and Synapse Formation
    causal_link_type: DIRECT
    hypothesis_groups:
    - lysosomal_autophagy_route
    description: >-
      Silencing Dmxl2 in cultured neurons reproduces the lysosomal and autophagic
      defect and costs those neurons neurite length and synapses.
  - target: Progressive Brain Atrophy and Leukoencephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - lysosomal_autophagy_route
    description: >-
      A sustained block in autophagic degradation is the plausible route to the
      progressive tissue loss seen on serial imaging, but no study has connected
      the two directly in this disease, so the intermediates are unstated.
- name: Impaired Synaptic Vesicle Loading
  description: >-
    Loading of neurotransmitter into a synaptic vesicle is driven by the proton
    gradient the vesicular V-ATPase generates. Where the pump cannot be assembled,
    vesicles are not filled. This node captures the single concept of a
    presynaptic vesicle-filling failure and is the entry point of the
    synaptic-vesicle hypothesis for the epilepsy.
  role: mediator
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: synaptic vesicle lumen acidification
    modifier: DECREASED
    term:
      id: GO:0097401
      label: synaptic vesicle lumen acidification
  evidence:
  - reference: PMID:40646309
    reference_title: "A heterotrimeric protein complex assembles the metazoan V-ATPase upon dissipation of proton gradients."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "In neurons, the V-ATPase is required to package certain neurotransmitters into synaptic vesicles"
    explanation: "States the dependence of vesicular neurotransmitter packaging on the V-ATPase. Evidence source is OTHER because this sentence is the paper's introductory background rather than its own experiment, and directness is INDIRECT because it is about the pump, not about DMXL2 loss."
  - reference: PMID:39273013
    reference_title: "V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "Rabconnectin-3α interacts with the synaptic vesicle (SV)-associated G-protein Rab3A at the synapse and is strictly involved in the assembly and incorporation of v-ATPase into SVs through its Rav1p domain, homologous to the yeast v-ATPase regulator Rav1p"
    explanation: "Connects DMXL2 specifically to getting the V-ATPase onto synaptic vesicles, which is what makes this node a DMXL2 consequence rather than a general statement about the pump. Evidence source is OTHER because this is a review; one of its authors co-authored the founding DEE81 report."
  downstream:
  - target: Neuronal Hyperexcitability and Hypersynchrony
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - synaptic_vesicle_route
    description: >-
      Proposed, not demonstrated: if synaptic vesicles cannot be filled, synaptic
      transmission fails and network activity becomes abnormal. No
      electrophysiological measurement has been made in a DEE81 neuron, so the
      intermediates between vesicle-filling failure and hypersynchrony are unknown.
    evidence:
    - reference: PMID:34249946
      reference_title: "RAVE and Rabconnectin-3 Complexes as Signal Dependent Regulators of Organelle Acidification."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: OTHER
      snippet: "which could suggest that loss of synaptic vesicle function is the basis of the aberrant neurological activity associated with DMXL2 deficiency"
      explanation: "The source states this as a suggestion, which is why the edge is indirect with unknown intermediates and is assigned to a hypothesis group rather than asserted. Evidence source is OTHER because this is a review."
- name: Impaired Neurite Elongation and Synapse Formation
  description: >-
    Neurons in which Dmxl2 is silenced show the same lysosomal and autophagic
    abnormalities as patient fibroblasts, and in addition fail to elongate their
    neurites and lose synapses. This node captures the single concept of a
    neuron-intrinsic failure to build normal processes and connections.
  role: mediator
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron projection morphogenesis
    modifier: DECREASED
    term:
      id: GO:0048812
      label: neuron projection morphogenesis
  - preferred_term: synapse assembly
    modifier: DECREASED
    term:
      id: GO:0007416
      label: synapse assembly
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    snippet: "Altered lysosomal homeostasis and defective autophagy were recapitulated in Dmxl2-silenced mouse hippocampal neurons, which exhibited impaired neurite elongation and synaptic loss."
    explanation: "Reproduces the cellular defect in neurons and adds the neurite and synapse phenotype. Evidence source is IN_VITRO because this is a cultured primary neuron preparation, not a whole animal."
  downstream:
  - target: Impaired Prenatal Brain Development
    causal_link_type: DIRECT
    description: >-
      Neurons that cannot extend processes or form synapses cannot build normal
      connectivity in the developing brain.
  - target: Neuronal Hyperexcitability and Hypersynchrony
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - lysosomal_autophagy_route
    description: >-
      Proposed, not demonstrated: abnormally wired networks with reduced synaptic
      density are the route to hypersynchronous discharge on this hypothesis. No
      excitability measurement has been reported in this model or in patient
      neurons.
- name: Impaired Prenatal Brain Development
  description: >-
    Connectivity fails to reach the expected stage by birth. Imaging in the first
    months of life already shows a thin corpus callosum and brain hypomyelination
    in every patient, which is a prenatal rather than a postnatal deficit. This
    node captures the single concept of an antenatally established structural
    brain deficit.
  role: mediator
  biological_scale: TISSUE
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all."
    explanation: "Structural evidence, present from the earliest imaging, that brain development was already abnormal before birth."
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "These clinical findings are consistent with a developmental brain disorder that begins in the prenatal brain, prevents neural connections from reaching the expected stages at birth, and follows a progressive course."
    explanation: "The authors' reading of the combined imaging and clinical data as a prenatal-onset developmental disorder with a progressive course."
  downstream:
  - target: Developmental Encephalopathy
    causal_link_type: DIRECT
    description: >-
      An antenatally established connectivity deficit is the developmental half of
      the developmental and epileptic encephalopathy.
  - target: Progressive Brain Atrophy and Leukoencephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The same brains that start hypomyelinated go on to shrink, but nothing
      published establishes whether the progressive loss is a continuation of the
      developmental lesion or a separate degenerative process.
  - target: Thin Corpus Callosum
    causal_link_type: DIRECT
    description: >-
      A commissure that failed to form normally is the imaging correlate of the
      antenatal connectivity deficit.
  - target: Cerebral Hypomyelination
    causal_link_type: DIRECT
    description: >-
      Deficient myelination on the earliest scans is the other imaging correlate
      of the same antenatal deficit.
- name: Neuronal Hyperexcitability and Hypersynchrony
  description: >-
    Populations of neurons fire excessively and synchronously. In DEE81 the
    signature is electrographic: the founding cohort's phenotype was Ohtahara
    syndrome, defined by a suppression-burst EEG in which high-amplitude
    synchronous bursts alternate with near-flat suppression, from the first weeks
    of life. This node captures the single concept of network hyperexcitability
    and conforms to the shared epilepsy final common pathway.
  role: central_effector
  biological_scale: CELLULAR
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: action potential
    modifier: INCREASED
    term:
      id: GO:0001508
      label: action potential
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability."
    explanation: "Defines the electroclinical syndrome these patients were shown to have; the suppression-burst pattern is the network-level signature of hypersynchronous discharge. Evidence source is OTHER and directness INDIRECT because this sentence defines Ohtahara syndrome generally rather than reporting a DEE81 measurement."
  downstream:
  - target: Neonatal-Onset Refractory Seizures
    causal_link_type: DIRECT
    description: >-
      Hypersynchronous network discharge is expressed clinically as seizures.
  - target: EEG with Burst Suppression
    causal_link_type: DIRECT
    description: >-
      Bursts of synchronous high-amplitude activity alternating with near-flat
      suppression are the electrographic expression of this network state.
- name: Neonatal-Onset Refractory Seizures
  description: >-
    The clinical endpoint of the epileptic arm: recurrent seizures beginning in the
    first day or days of life that do not respond to antiseizure medication. This
    node captures the single concept of the drug-resistant seizure state and
    conforms to the shared epilepsy final common pathway.
  role: consequence
  biological_scale: ORGANISM
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
    explanation: "Dates onset to the first day of life and names the accompanying syndromic features."
  - reference: PMID:40180340
    reference_title: "Neonate with developmental and epileptic encephalopathy 81 (DEE81): lessons learnt and future implications."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite initial treatment with multiple antiepileptics, seizures persisted, prompting a thorough diagnostic evaluation."
    explanation: "Documents drug resistance in an independently reported DEE81 neonate."
  downstream:
  - target: Seizure
    causal_link_type: DIRECT
    description: >-
      This node is the mechanism-side statement of the clinical seizure
      phenotype.
  - target: Focal-Onset Seizure
    causal_link_type: DIRECT
    description: >-
      Focal onset is the semiology recorded in the one patient described outside
      the founding cohort.
  - target: Epileptic Encephalopathy
    causal_link_type: DIRECT
    description: >-
      Refractory seizures from the first day of life, together with the
      developmental impairment, constitute the epileptic encephalopathy.
  - target: Developmental Encephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Continuous early-life epileptic activity is conventionally held to worsen
      development, and it is the epileptic half of the name, but in DEE81 the
      developmental deficit is already present at birth and no study separates the
      seizure-driven contribution from the antenatal one.
- name: Developmental Encephalopathy
  description: >-
    Profound, non-progressing-forward developmental impairment: patients acquired no
    developmental, communicative or motor skill after birth. Both the antenatal
    connectivity deficit and the neonatal-onset epilepsy converge here. This node
    captures the single concept of the developmental half of the syndrome.
  role: consequence
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth."
    explanation: "Records the absence of any developmental attainment across the founding cohort."
  downstream:
  - target: Profound Global Developmental Delay
    causal_link_type: DIRECT
    description: >-
      The clinical measure of this node is the complete absence of developmental
      attainment.
- name: Progressive Brain Atrophy and Leukoencephalopathy
  description: >-
    Serial imaging shows the brain losing volume, with white-matter disease, over
    follow-up - a degenerative course superimposed on the developmental deficit.
    This node captures the single concept of progressive structural brain loss and
    is what distinguishes DEE81 from a static encephalopathy.
  role: consequence
  biological_scale: TISSUE
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
    explanation: "Serial imaging in three of the six patients documents progressive volume loss with white-matter change."
  downstream:
  - target: Cerebral Atrophy
    causal_link_type: DIRECT
    description: >-
      Progressive volume loss is reported on serial MRI as brain shrinkage.
  - target: Leukoencephalopathy
    causal_link_type: DIRECT
    description: >-
      White-matter disease accompanies the volume loss on the same scans.
phenotypes:
- name: Epileptic Encephalopathy
  category: Neurological
  description: >-
    The defining electroclinical picture: intractable seizures from the first day
    of life with profound developmental impairment, presenting as Ohtahara
    syndrome.
  phenotype_term:
    preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
    onset:
      onset_category: NEONATAL
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
    explanation: "States the epileptic encephalopathy and its first-day-of-life onset."
- name: Seizure
  category: Neurological
  description: >-
    Seizures are universal and refractory. The founding cohort presented as
    Ohtahara syndrome; the one later-reported neonate had refractory focal
    seizures.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    onset:
      onset_category: NEONATAL
  frequency: OBLIGATE
  evidence:
  - reference: PMID:40180340
    reference_title: "Neonate with developmental and epileptic encephalopathy 81 (DEE81): lessons learnt and future implications."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report the case of a neonate born from a consanguineous marriage, presenting with refractory focal seizures shortly after birth."
    explanation: "An independently reported DEE81 patient with refractory seizures from shortly after birth."
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
    explanation: "Covers the six patients of the founding cohort, all of whom had the epileptic encephalopathy from the first day of life."
  notes: >-
    OBLIGATE rests on all seven reported patients having seizures - the six of the
    founding cohort, whose electroclinical diagnosis was Ohtahara syndrome, and the
    one later neonate. Seizures are also definitional for a developmental and
    epileptic encephalopathy, so the denominator is small but the claim is not in
    doubt.
- name: Focal-Onset Seizure
  category: Neurological
  description: >-
    Focal-onset seizures were the presenting semiology in the one DEE81 patient
    reported outside the founding cohort.
  phenotype_term:
    preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: PMID:40180340
    reference_title: "Neonate with developmental and epileptic encephalopathy 81 (DEE81): lessons learnt and future implications."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report the case of a neonate born from a consanguineous marriage, presenting with refractory focal seizures shortly after birth."
    explanation: "Names the seizure onset as focal in this patient."
  notes: >-
    Recorded from a single case. The founding cohort is described at the level of
    the Ohtahara electroclinical syndrome rather than by individual semiology, so
    no frequency is asserted.
- name: EEG with Burst Suppression
  category: Neurological
  description: >-
    Suppression-burst is the EEG signature of Ohtahara syndrome, the electroclinical
    diagnosis carried by every patient of the founding cohort.
  phenotype_term:
    preferred_term: EEG with burst suppression
    term:
      id: HP:0010851
      label: EEG with burst suppression
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability."
    explanation: "Defines suppression-burst as the EEG pattern of Ohtahara syndrome, which is the diagnosis these patients were given. Directness is INDIRECT and the source is OTHER because this sentence defines the syndrome rather than reporting these patients' recordings."
- name: Profound Global Developmental Delay
  category: Neurological
  description: >-
    No developmental, communicative or motor skill was acquired after birth in any
    patient of the founding cohort.
  phenotype_term:
    preferred_term: Profound global developmental delay
    term:
      id: HP:0012736
      label: Profound global developmental delay
  frequency: OBLIGATE
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth."
    explanation: "Absence of any skill acquisition in all six patients is the profound end of the developmental-delay scale."
  notes: >-
    The denominator for OBLIGATE is the six patients of the founding cohort, in
    all of whom no skill was acquired. The one later-reported patient was a
    neonate at the time of publication, so no developmental outcome is available.
- name: Hearing Impairment
  category: Neurological
  description: >-
    Deafness accompanies the encephalopathy and is one of the features that make
    DEE81 syndromic rather than an isolated epilepsy.
  phenotype_term:
    preferred_term: Deafness
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
    explanation: "Names deafness as an accompanying feature of the syndrome."
  notes: >-
    Bound to HP:0000365 Hearing impairment rather than to the sensorineural
    child term, because the source says only "deafness". Narrowing it to
    sensorineural would have to be argued from the DFNA71 hair-cell literature,
    which this entry deliberately does not cite for DEE81 claims; taking the
    binding from a source about a different disease is the error the narrower
    term would encode. If a DEE81 report gives audiological detail, the term can
    be specialised then.
- name: Peripheral Neuropathy
  category: Neurological
  description: >-
    A mild peripheral polyneuropathy accompanies the encephalopathy.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
    severity: MILD
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
    explanation: "Names a mild peripheral polyneuropathy as an accompanying feature."
- name: Abnormal Facial Shape
  category: Craniofacial
  description: >-
    Dysmorphic features accompany the encephalopathy. The founding report does not
    itemise them in the abstract, so only the general finding is curated.
  phenotype_term:
    preferred_term: Dysmorphic features
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
    explanation: "Names dysmorphic features as an accompanying finding."
- name: Thin Corpus Callosum
  category: Neurological
  description: >-
    A thin corpus callosum was present on the earliest MRI in every patient.
  phenotype_term:
    preferred_term: Thin corpus callosum
    term:
      id: HP:0033725
      label: Thin corpus callosum
  frequency: OBLIGATE
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all."
    explanation: "Reports a thin corpus callosum in all patients on early imaging."
  notes: >-
    "In all" in the source means all six patients of the founding cohort, which is
    the denominator behind OBLIGATE here.
- name: Cerebral Hypomyelination
  category: Neurological
  description: >-
    Brain hypomyelination was present on the earliest MRI in every patient.
  phenotype_term:
    preferred_term: Cerebral hypomyelination
    term:
      id: HP:0006808
      label: Cerebral hypomyelination
  frequency: OBLIGATE
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all."
    explanation: "Reports brain hypomyelination in all patients on early imaging."
  notes: >-
    As for the thin corpus callosum, "in all" is all six patients of the founding
    cohort.
- name: Cerebral Atrophy
  category: Neurological
  description: >-
    Follow-up imaging shows progressive brain shrinkage, in three of the six
    patients in whom serial scans were available.
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
    explanation: "Documents progressive brain volume loss on serial imaging."
  notes: >-
    The denominator is the three patients who had follow-up scans, not the whole
    cohort, so no frequency is asserted.
- name: Leukoencephalopathy
  category: Neurological
  description: >-
    White-matter disease appears alongside the progressive volume loss on
    follow-up imaging.
  phenotype_term:
    preferred_term: Leukoencephalopathy
    term:
      id: HP:0002352
      label: Leukoencephalopathy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
    explanation: "Reports leukoencephalopathy on follow-up imaging."
  notes: >-
    As for cerebral atrophy, the denominator is the three patients with serial
    scans.
differential_diagnoses:
- name: Other genetic causes of Ohtahara syndrome
  description: >-
    Ohtahara syndrome is an electroclinical diagnosis, not an aetiology: the same
    neonatal suppression-burst picture is produced by variants in many different
    genes, so identifying Ohtahara syndrome does not identify DEE81. The founding
    report says exactly this, which is why the cohort needed exome sequencing to
    be resolved.
  distinguishing_features:
  - >-
      Three features separate DEE81 from a typical channelopathy or synaptopathy
      Ohtahara syndrome. It is syndromic - deafness, mild peripheral polyneuropathy
      and dysmorphic features accompany the epilepsy. Its early MRI is abnormal,
      with a thin corpus callosum and hypomyelination in every patient, where many
      other Ohtahara aetiologies have normal early imaging. And it is progressive,
      with brain shrinkage and leukoencephalopathy on follow-up scans. Inheritance
      is recessive, so an affected sibling pair is expected and a de novo variant
      is not.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability."
    explanation: "States the aetiological heterogeneity that makes the electroclinical diagnosis insufficient on its own. Evidence source is OTHER because this sentence is the paper's background definition."
  notes: >-
    Individual alternative aetiologies are not enumerated here, because the DEE81
    sources do not list them and inventing a gene list would not be sourced. The
    knowledge base curates several of them separately, including
    STXBP1_Encephalopathy, KCNQ2_Developmental_and_Epileptic_Encephalopathy and
    SCN2A-Related_Developmental_and_Epileptic_Encephalopathy.
- name: STXBP1 encephalopathy
  description: >-
    The best-characterised single-gene cause of Ohtahara syndrome, and the one a
    neonate with refractory seizures on a suppression-burst EEG is most likely to
    be tested for. About a fifth of STXBP1 patients present as Ohtahara syndrome.
  disease_term:
    preferred_term: STXBP1 encephalopathy
    term:
      id: MONDO:0012812
      label: developmental and epileptic encephalopathy, 4
  distinguishing_features:
  - >-
      Zygosity is the cleanest discriminator. STXBP1 encephalopathy is caused by
      heterozygous variants acting through haploinsufficiency, so it is dominant
      and typically de novo; DEE81 is recessive, and in the founding cohort every
      family had two affected siblings. A recurrence in siblings therefore argues
      for DEE81 and against STXBP1.
  - >-
      The DEE81-specific findings are the positive discriminators: deafness, mild
      peripheral polyneuropathy and dysmorphic features accompanying the epilepsy,
      a thin corpus callosum with hypomyelination on the earliest MRI, and
      progressive brain shrinkage with leukoencephalopathy on follow-up. These are
      stated from the DEE81 side; this entry does not assert what STXBP1 imaging
      or extraneural features look like, because its sources do not cover that.
  evidence:
  - reference: PMID:18469812
    reference_title: "De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early infantile epileptic encephalopathy with suppression-burst (EIEE), also known as Ohtahara syndrome, is one of the most severe and earliest forms of epilepsy."
    explanation: "Anchors STXBP1 to the same Ohtahara/suppression-burst presentation DEE81 produces."
  - reference: PMID:26865513
    reference_title: "STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "While one-third of patients presented with Ohtahara syndrome (21%) or West syndrome (9.5%), the majority has a nonsyndromic early-onset epilepsy and encephalopathy (53%) with epileptic spasms or tonic seizures as main seizure type."
    explanation: "Quantifies how often STXBP1 presents as Ohtahara syndrome, which is what makes it the leading differential."
  - reference: PMID:18469812
    reference_title: "De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings suggest that haploinsufficiency of STXBP1 causes EIEE."
    explanation: "Establishes the dominant, haploinsufficiency mechanism, which is the discriminator against recessive DEE81."
progression:
- phase: Neonatal presentation
  age_range: First day of life
  notes: >-
    Seizures begin on the first day of life, on a suppression-burst EEG
    background, and are refractory to multiple antiseizure medications from the
    outset.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features."
    explanation: "Dates the onset of the encephalopathy to the first day of life."
- phase: Developmental arrest from birth
  notes: >-
    Milestones are not merely delayed: no patient of the founding cohort acquired
    any developmental, communicative or motor skill after birth. The structural
    correlate is already visible on the first MRI, as a thin corpus callosum with
    hypomyelination.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth."
    explanation: "Records that no skill was acquired at any point after birth."
- phase: Progressive neurodegenerative course
  notes: >-
    On follow-up imaging the brain shrinks and develops leukoencephalopathy, so
    the course is degenerative as well as developmental. This is the feature the
    founding report treats as distinguishing.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
    explanation: "Serial imaging showing progressive structural loss."
- phase: Death in childhood
  age_range: Within the first 9 years of life
  notes: >-
    Five of the six patients of the founding cohort died within the first nine
    years of life. Fatal outcome is recorded here rather than as a phenotype
    because HPO files death in infancy and childhood under clinical course rather
    than under phenotypic abnormality.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth."
    explanation: "Reports mortality in five of the six patients within the first nine years."
genetic:
- name: DMXL2
  gene_term:
    preferred_term: DMXL2
    term:
      id: hgnc:2938
      label: DMXL2
  association: Causative
  features: >-
    Biallelic loss-of-function DMXL2 alleles cause DEE81. Reported genotypes are
    homozygous or compound heterozygous and include nonsense (p.Ser1493*),
    splice-acceptor (c.7518-1G>A, predicted p.Trp2507Argfs*4) and missense
    (p.Ala1712Val) substitutions; patient fibroblasts carry no detectable DMXL2
    protein, so the alleles behave as nulls at the protein level. Heterozygous
    carriers in these families were unaffected. DMXL2 encodes
    rabconnectin-3alpha, a subunit of the metazoan RAVE complex that assembles the
    vacuolar H+-ATPase.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Siblings in Family 1 were compound heterozygous for the c.5135C>T (p.Ala1712Val) missense substitution and the c.4478C>G (p.Ser1493*) nonsense substitution; in Family 2 were homozygous for the c.4478C>A (p.Ser1493*) nonsense substitution and in Family 3 were homozygous for the c.7518-1G>A (p.Trp2507Argfs*4) substitution."
    explanation: "The causal genotypes reported across the three founding families."
  - reference: PMID:34249946
    reference_title: "RAVE and Rabconnectin-3 Complexes as Signal Dependent Regulators of Organelle Acidification."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "DMXL2 (Rabconnectin-3α) and WDR7 (Rabconnectin-3β) together comprise a synaptic Rabconnectin-3 complex in an apparent 1:1 ratio (Kawabe et al., 2003)."
    explanation: "Identifies the gene product as rabconnectin-3alpha and its obligate partner. Evidence source is OTHER because this is a review."
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    Seven patients are reported as this disease: six from the three founding
    families, and one later consanguineous neonate. An eighth homozygous DMXL2
    patient exists in the literature but is counted here as unresolved rather
    than as a DEE81 case - see the dmxl2_phenotypic_expansion discussion, where
    the primary report and a later review disagree about whether that phenotype
    belongs to this entity. No population rate has been estimated, so no numeric
    prevalence is asserted.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using whole exome sequencing, we identified biallelic DMXL2 mutations in three sibling pairs with Ohtahara syndrome, belonging to three unrelated families."
    explanation: "Accounts for six of the seven reported patients."
diagnosis:
- name: Molecular Genetic Testing
  description: >-
    The diagnosis is molecular: identification of biallelic pathogenic DMXL2
    variants in a neonate with early-onset refractory seizures. Both published
    reports reached DEE81 that way - the founding cohort by whole exome
    sequencing, the later case by targeted genomic testing - and there is no
    biochemical marker to screen for.
  diagnosis_term:
    preferred_term: Genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:40180340
    reference_title: "Neonate with developmental and epileptic encephalopathy 81 (DEE81): lessons learnt and future implications."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "This case underscores the importance of considering genetic aetiologies in neonates with early-onset seizures and highlights the value of targeted genetic analysis in guiding personalised management strategies."
    explanation: "States the diagnostic role of genetic testing in a neonate with early-onset seizures."
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using whole exome sequencing, we identified biallelic DMXL2 mutations in three sibling pairs with Ohtahara syndrome, belonging to three unrelated families."
    explanation: "Exome sequencing is how the founding cohort was diagnosed."
- name: Brain MRI
  description: >-
    Imaging supports the diagnosis rather than making it, but it is informative
    in both directions. Unlike many DEEs, early MRI in DEE81 is not normal: a
    thin corpus callosum with hypomyelination was present in every patient in the
    first months of life, and repeat imaging shows progressive shrinkage with
    leukoencephalopathy. A normal early scan would therefore argue against DEE81.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all."
    explanation: "Early MRI is abnormal in every patient, which is what gives it diagnostic value here."
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy."
    explanation: "Repeat imaging adds the progressive component, which distinguishes DEE81 from a static encephalopathy."
- name: Electroencephalography
  description: >-
    EEG establishes the electroclinical syndrome. Every patient of the founding
    cohort was diagnosed with Ohtahara syndrome, which is defined by a
    suppression-burst pattern in the first weeks of life.
  evidence:
  - reference: PMID:31688942
    reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability."
    explanation: "Defines the EEG pattern that identifies the electroclinical syndrome these patients were given. Evidence source is OTHER and directness INDIRECT because this sentence defines Ohtahara syndrome rather than reporting these patients' recordings."
treatments:
- name: Antiseizure Medication
  description: >-
    Multiple antiseizure medications were used in the one DEE81 patient whose
    treatment course is described, and seizures persisted. No disease-modifying
    therapy exists, and no antiseizure agent has been reported to control seizures
    in this disorder.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:40180340
    reference_title: "Neonate with developmental and epileptic encephalopathy 81 (DEE81): lessons learnt and future implications."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite initial treatment with multiple antiepileptics, seizures persisted, prompting a thorough diagnostic evaluation."
    explanation: "Documents that multiple antiseizure medications were given and did not control the seizures."
  notes: >-
    No specific agent is named as effective in either report, so no
    therapeutic_agent is bound. The evidence here is that antiseizure medication
    was tried and failed, not that it is a recommended therapy.

    No target_mechanisms link is asserted either, and that is deliberate rather
    than an omission. TreatmentEffectEnum offers INHIBITS, ACTIVATES, MODULATES,
    BYPASSES and RESTORES; every one of them would claim an effect on
    Neuronal Hyperexcitability and Hypersynchrony that the only cited evidence
    contradicts, since the seizures persisted. Antiseizure medications do act on
    neuronal excitability as a class, but in this disease that is the intent, not
    the observed outcome, and the enum has no value for an intended target that
    failed. Recording the failure in prose is more accurate than encoding an
    effect that did not occur.
experimental_models:
- name: DEE81 patient-derived skin fibroblasts
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: >-
    Primary dermal fibroblasts from affected individuals, which contain no
    detectable DMXL2 protein and reproduce the endolysosomal and autophagic
    defect. The most direct human model of the cellular lesion, but a
    non-neuronal one.
  publication: PMID:31688942
  modeled_mechanisms:
  - target: Defective Endolysosomal Acidification
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Cells carrying the patients' own genotype show the endolysosomal
      abnormality directly.
    limitations: >-
      Fibroblasts are not neurons and express the ubiquitous DMXL1 paralogue,
      so the magnitude of the defect in a fibroblast is not a guide to its
      magnitude in a brain-enriched, DMXL2-dependent cell.
    readouts:
    - name: LysoTracker signal and endolysosomal marker abundance
      target: Defective Endolysosomal Acidification
      direction: ALTERED
      interpretation: >-
        Increased LysoTracker signal with reduced endolysosomal markers and
        reduced degradative capacity is the measured correlate of this node.
      evidence:
      - reference: PMID:31688942
        reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
        supports: SUPPORT
        directness: DIRECT
        evidence_source: IN_VITRO
        snippet: "Patients' fibroblasts also exhibited an increased LysoTracker® signal associated with decreased endolysosomal markers and degradative processes."
        explanation: "The measurement itself, made in patient fibroblasts."
    evidence:
    - reference: PMID:31688942
      reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      snippet: "Expression analysis in patient-derived skin fibroblasts demonstrated absence of the DMXL2 protein, revealing a loss of function phenotype."
      explanation: "Establishes that these cells are a genuine null model of the patients' lesion, which is why they are informative for this node."
  - target: Impaired Autophagic Degradation
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      The autophagic block is demonstrated in the same patient cells by several
      independent assays.
    limitations: >-
      Autophagic flux was assessed in a dividing, non-neuronal cell type; neurons
      are post-mitotic and far more dependent on basal autophagy, so the
      consequences of the same block are not necessarily comparable.
    readouts:
    - name: LC3-II, p62 and polyubiquitinated protein levels
      target: Impaired Autophagic Degradation
      direction: ALTERED
      interpretation: >-
        Lower LC3-II with accumulation of p62 and polyubiquitinated proteins, plus
        abnormal autolysosomal ultrastructure, is the measured correlate of a
        blocked autophagic pathway.
      evidence:
      - reference: PMID:31688942
        reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
        supports: SUPPORT
        directness: DIRECT
        evidence_source: IN_VITRO
        snippet: "Defective endolysosomal homeostasis was accompanied by impaired autophagy, revealed by lower LC3II signal, accumulation of polyubiquitinated proteins, and autophagy receptor p62, with morphological alterations of the autolysosomal structures on electron microscopy."
        explanation: "The multi-assay measurement of the autophagic block."
    evidence:
    - reference: PMID:31688942
      reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      snippet: "Expression analysis in patient-derived skin fibroblasts demonstrated absence of the DMXL2 protein, revealing a loss of function phenotype."
      explanation: "The cells are protein-null for DMXL2, so an autophagic defect measured in them is attributable to the disease lesion."
- name: Dmxl2-silenced mouse hippocampal neuron culture
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: >-
    Cultured primary mouse hippocampal neurons in which Dmxl2 is knocked down.
    The only neuronal model reported for this disease, and the only place the
    neurite and synapse phenotype has been observed.
  publication: PMID:31688942
  modeled_mechanisms:
  - target: Impaired Neurite Elongation and Synapse Formation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Silencing Dmxl2 in neurons reproduces the lysosomal and autophagic defect
      seen in patient cells and adds the neuron-specific consequence: neurites
      fail to elongate and synapses are lost.
    limitations: >-
      This is acute RNA-interference knockdown in mouse neurons, not a
      constitutive biallelic human null, so residual protein and off-target
      effects are not excluded; and it is a dissociated culture, which cannot
      report the network-level excitability that would connect this node to the
      seizures.
    readouts:
    - name: Neurite length and synapse number
      target: Impaired Neurite Elongation and Synapse Formation
      direction: DECREASED
      interpretation: >-
        Reduced neurite elongation and synaptic loss are the measured correlates
        of this node.
      evidence:
      - reference: PMID:31688942
        reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
        supports: SUPPORT
        directness: DIRECT
        evidence_source: IN_VITRO
        snippet: "Altered lysosomal homeostasis and defective autophagy were recapitulated in Dmxl2-silenced mouse hippocampal neurons, which exhibited impaired neurite elongation and synaptic loss."
        explanation: "The measurement of neurite and synapse loss in Dmxl2-silenced neurons."
    evidence:
    - reference: PMID:31688942
      reference_title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      snippet: "Altered lysosomal homeostasis and defective autophagy were recapitulated in Dmxl2-silenced mouse hippocampal neurons, which exhibited impaired neurite elongation and synaptic loss."
      explanation: "The same sentence establishes that the model reproduces the patient-cell defect, which is what makes it informative for this node."
animal_models:
- name: Dmxl2 heterozygous mouse
  species: Mouse
  genotype: Dmxl2 heterozygous null
  publication: PMID:39273013
  description: >-
    The only viable mouse genotype available for this gene. Complete loss of
    Dmxl2 is embryonic lethal in mice, so the genotype that matches the patients
    - biallelic null - cannot be studied in a whole animal. Heterozygous mice are
    viable and show macrocephaly and corpus callosum dysplasia.
  genes:
  - preferred_term: DMXL2
    term:
      id: hgnc:2938
      label: DMXL2
  evidence:
  - reference: PMID:39273013
    reference_title: "V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "Complete loss of Dmxl2 is lethal at the embryonic stage in mice"
    explanation: "The homozygous null, which is the genotype matching the patients, does not survive to birth in mice - which is why the heterozygote is the only viable mouse. Evidence source is OTHER because this is a review reporting other groups' mouse work rather than an original animal study."
  modeled_mechanisms:
  - target: Impaired Prenatal Brain Development
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Corpus callosum dysplasia in the heterozygous mouse is the one finding that
      lines up with the human disease, where a thin corpus callosum is present on
      the earliest MRI of every patient. It supports the claim that DMXL2 dosage
      matters for commissural development.
    limitations: >-
      The zygosity is wrong. DEE81 is recessive and the heterozygous carriers in
      all three founding families were clinically unaffected, so a mouse that is
      abnormal at half dosage is not modelling the human carrier state either.
      The mouse also has macrocephaly, which the founding cohort does not, and
      none of the defining features of the disease - neonatal seizures,
      suppression-burst EEG, deafness, progressive atrophy - is reported in it.
      The matched homozygous null is embryonic lethal, so the fidelity of this
      model to the human recessive disease is low by construction rather than by
      measurement.
    readouts:
    - name: Corpus callosum morphology
      target: Impaired Prenatal Brain Development
      direction: ALTERED
      interpretation: >-
        Callosal dysplasia at half Dmxl2 dosage is the murine counterpart of the
        thin corpus callosum seen on early human MRI.
      evidence:
      - reference: PMID:39273013
        reference_title: "V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities."
        supports: SUPPORT
        directness: DIRECT
        evidence_source: OTHER
        snippet: "heterozygous DMXL2 mice show macrocephaly and corpus callosum dysplasia"
        explanation: "The reported callosal and head-size findings in the heterozygous mouse."
    evidence:
    - reference: PMID:39273013
      reference_title: "V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: OTHER
      snippet: "uncovering the relevance of early v-ATPase regulation in brain development and function"
      explanation: "The review's own reading of why the mouse dosage phenotype is informative for brain development, which is the claim that makes this model relevant to this node. Directness is INDIRECT because it is a general statement about v-ATPase regulation rather than about DEE81."
discussions:
- discussion_id: dee81_no_whole_animal_model
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Every mechanistic result in DEE81 comes from a fibroblast or a dissociated
    neuron culture, and the mouse genotype that matches the patients does not
    survive to birth. How much of the human disease can the available models
    actually speak to?
  attaches_to:
  - animal_models#Mouse
  - experimental_models#Dmxl2-silenced mouse hippocampal neuron culture
  - pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
  rationale: >-
    Complete loss of Dmxl2 is embryonic lethal in mice, so no whole-organism
    model of the recessive human genotype exists; the viable heterozygote has the
    wrong zygosity and a phenotype (macrocephaly) the patients do not have. The
    two systems that do carry the human lesion - patient fibroblasts and
    Dmxl2-silenced neurons - are both cultures, and neither can produce a
    seizure, an EEG, myelin, or a progressive atrophy. That is why the edges from
    the cellular defects to network hyperexcitability are marked
    INDIRECT_UNKNOWN_INTERMEDIATES: the gap is not that nobody has looked, it is
    that the systems available cannot look.
  evidence:
  - reference: PMID:39273013
    reference_title: "V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "Complete loss of Dmxl2 is lethal at the embryonic stage in mice"
    explanation: "Establishes that the genotype-matched whole-animal model cannot be made by simple knockout."
  proposed_experiments:
  - experiment_id: dee81_hypomorphic_and_conditional_mouse
    name: Conditional or hypomorphic Dmxl2 mouse carrying a human DEE81 allele
    description: >-
      Because the constitutive null is embryonic lethal, a viable model needs
      either a conditional allele deleted after the lethal window or a knock-in of
      a human DEE81 allele that leaves the residual function compatible with
      survival. Phenotyping would need EEG, myelination and serial imaging, since
      those are the features no current model can report.
    would_support:
    - pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
    - pathophysiology#Impaired Prenatal Brain Development
    supporting_outcome:
    - >-
      Neonatal-onset seizures with a discontinuous EEG, hypomyelination and
      progressive volume loss in a viable Dmxl2 mouse would put the human
      mechanism chain on whole-organism footing.
    refuting_outcome:
    - >-
      A viable Dmxl2 mouse with the cellular lysosomal phenotype but no seizures
      and normal myelination would argue that the human epilepsy depends on
      something the mouse does not share, and would move the mismatch from
      "untested" to "tested and divergent".
- discussion_id: dmxl2_phenotypic_expansion
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Is the milder DMXL2 phenotype - intellectual disability with epilepsy,
    macrocephaly and dysmorphism, but without neonatal Ohtahara syndrome, deafness
    or early death - part of DEE81, or a separate allelic disorder?
  attaches_to:
  - genetic#DMXL2
  - prevalence#Worldwide
  rationale: >-
    A homozygous DMXL2 truncating variant was reported in a child with
    intellectual disability, epilepsy, macrocephaly and dysmorphism. The reporting
    group classified it as a phenotype different enough from the published DMXL2
    associations to represent a phenotypic expansion or a potentially distinct
    allelic disorder, and contrasted it explicitly with the endocrine phenotype.
    A later review counts the same patient as an additional DMXL2 developmental
    and epileptic encephalopathy case. Both readings are defensible from the
    published text and they give different answers to how many DEE81 patients
    exist, which is why the prevalence record here counts only the seven patients
    described as this disease. Resolving it needs the residual-function question
    answered: the polyendocrine phenotype is reported with a variant retaining
    partial transcript, and whether this child's truncating allele leaves residual
    protein has not been measured.
  evidence:
  - reference: PMID:30237576
    reference_title: "Autozygome and high throughput confirmation of disease genes candidacy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also found that DMXL2 harbors a homozygous truncating variant"
    explanation: "The primary report of the additional homozygous DMXL2 patient at issue."
  - reference: PMID:30237576
    reference_title: "Autozygome and high throughput confirmation of disease genes candidacy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "although the associated phenotypes are sufficiently different from the original reports that they represent phenotypic expansion or potentially distinct allelic disorders"
    explanation: "The reporting group's own classification of this class of finding, which is what makes the assignment genuinely open rather than settled."
  - reference: PMID:39273013
    reference_title: "V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "An additional homozygous variant in DMXL2 has been reported in a patient with consanguineous parents and presenting DEE and macrocephaly"
    explanation: "The later review counts the same patient as a DMXL2 DEE case, which is the competing reading. Evidence source is OTHER because this is a review."
- discussion_id: dee81_seizure_route
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Which arm of the V-ATPase assembly failure actually generates the seizures in
    DEE81 - the presynaptic vesicle-filling failure, or the lysosomal and
    autophagic block with its consequences for neurite and synapse development?
  attaches_to:
  - pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
  - pathophysiology#Impaired Synaptic Vesicle Loading
  - pathophysiology#Impaired Neurite Elongation and Synapse Formation
  rationale: >-
    Both routes are supported at the level of cell biology and neither has been
    tested against network excitability. The published patient-cell work
    establishes the lysosomal and autophagic block; the synaptic-vesicle route is
    stated as a suggestion in a review. No electrophysiological recording has been
    reported from a DEE81 neuron or from a Dmxl2-deficient network, so the step
    from either cellular defect to hypersynchronous discharge is unmeasured. This
    matters therapeutically: the two routes imply different intervention points.
  proposed_experiments:
  - experiment_id: dee81_neuron_excitability_phenotyping
    name: Excitability phenotyping of DEE81 patient-derived neurons
    description: >-
      Differentiate neurons from DEE81 patient iPSCs and from isogenic corrected
      controls, plate on multi-electrode arrays, and record spontaneous and evoked
      network activity alongside vesicular pH, vesicular neurotransmitter content,
      autophagic flux, neurite length and synapse density in the same cultures.
      Selective pharmacological or genetic rescue of vesicular acidification
      versus of autophagic flux would then separate the two routes.
    would_support:
    - pathophysiology#Impaired Synaptic Vesicle Loading
    - pathophysiology#Impaired Neurite Elongation and Synapse Formation
    supporting_outcome:
    - >-
      Network hyperexcitability that is corrected by rescuing one arm and not the
      other identifies that arm as the proximate route to the epilepsy.
    refuting_outcome:
    - >-
      Hyperexcitability that persists when both arms are rescued individually, or
      absent network hyperexcitability in a genuinely null neuron, would indicate
      that neither cellular defect is the proximate cause.
- discussion_id: dmxl2_allelic_heterogeneity
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Why does DMXL2 produce three clinically distinct human phenotypes - recessive
    DEE81, dominant non-syndromic deafness DFNA71, and a polyendocrine and
    polyneuropathy syndrome - and what determines which one a given allele causes?
  attaches_to:
  - genetic#DMXL2
  rationale: >-
    Distinguishing these entities is a practical curation and diagnostic problem,
    not only a mechanistic one: a gene-level literature or variant search on DMXL2
    returns all three, and their evidence must not be mixed. Zygosity is the
    obvious axis - DEE81 and the polyendocrine syndrome are biallelic while DFNA71
    is heterozygous - but nothing published explains why one biallelic
    loss-of-function genotype produces a neonatal encephalopathy and another
    produces an endocrine and peripheral-nerve phenotype, and no allelic series
    with matched functional measurements exists. Note also that heterozygous
    DMXL2 deletions occur incidentally in aromatase excess syndrome, where the
    causal lesion is a neighbouring CYP19A1 rearrangement; those carriers are not
    reported to have any DMXL2-attributable phenotype.
  evidence:
  - reference: PMID:34249946
    reference_title: "RAVE and Rabconnectin-3 Complexes as Signal Dependent Regulators of Organelle Acidification."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "Mutations in DMXL2 have been connected to Ohtahara Syndrome, nonsyndromic hearing loss, and neuroendocrine dysfunction (Tata et al., 2014; Chen et al., 2017; Esposito et al., 2019)."
    explanation: "Establishes that DMXL2 carries three distinct disease associations, which is the premise of this gap. Evidence source is OTHER because this is a review."
notes: >-
  Scope. Only sources about the biallelic, recessive neurological phenotype are
  cited for disease claims. DMXL2 also causes autosomal dominant non-syndromic
  deafness DFNA71 and a polyendocrine and polyneuropathy syndrome, and the mouse
  and hair-cell literature on Dmxl2 is largely written against the deafness
  phenotype; none of it is used here to support a DEE81 claim. The DMXL2 mentions
  in Aromatase_Excess_Syndrome are a neighbouring-locus artefact - heterozygous
  15q21.2 rearrangements that delete DMXL2 exons while creating a chimeric
  CYP19A1 transcript - and are not coverage of this disease.

  Evidence grading. PMID:31688942 is deliberately graded three ways, because it
  reports three kinds of study: the family genotypes, clinical course and MRI are
  HUMAN_CLINICAL; the fibroblast and cultured-neuron experiments are IN_VITRO;
  and the sentences that summarise DMXL2 function or define Ohtahara syndrome are
  OTHER, because they are background rather than results of this study. The
  Dmxl2-silenced hippocampal neurons are IN_VITRO and not MODEL_ORGANISM: they
  are a dissociated primary culture, not a whole animal.

  Three phenotypes are deliberately left unattached to the pathograph:
  hearing impairment, peripheral neuropathy and dysmorphic features. They are
  well attested clinically - the founding report names all three - but no source
  explains how loss of DMXL2 produces them, and DEE81 has no reported extraneural
  mechanism work at all. Drawing an edge from any existing node to them would be
  asserting a mechanism nobody has shown. The hair-cell work that would speak to
  the deafness is written against DFNA71 and is not used here for the reason
  given above.

  Deep-research cross-check. A falcon deep-research run
  (research/Developmental_And_Epileptic_Encephalopathy_81-deep-research-falcon.md,
  19 citations) passed the NEC gate against MONDO:0032858 with DMXL2 the dominant
  gene at 49 mentions and no competing gene, and its content is DEE81-specific
  throughout - it separates the three DMXL2 diseases explicitly rather than
  blending them. Comparing it against this entry surfaced four things, all
  incorporated: the Falace 2024 V-ATPase review as the source for DMXL2's role in
  getting the pump onto synaptic vesicles, the mouse genetics (embryonic lethal
  null, macrocephalic heterozygote), the additional homozygous DMXL2 patient
  reported by Maddirevula et al., and the model-fidelity problem that follows
  from the lethal null.

  It also surfaced findings that could not be curated, and the reason is a cache
  limit rather than a judgement: the report reads the founding paper's full text,
  while references_cache/PMID_31688942.md is abstract-only. Brain 2019 is not
  deposited in PMC (checked), so there is no route to the full text through the
  reference fetcher, and an evidence item needs an exact quote from cached text.
  The uncurated findings are per-patient seizure semiology (tonic predominant,
  some myoclonic), hypotonia and quadriparesis in 6/6, simplified gyral pattern
  in 2/6, the specification of the deafness as sensorineural in 6/6, and the
  rescue of the fibroblast lysosomal phenotype by wild-type DMXL2 re-expression.
  Each is a real finding from the paper's results section and each should be
  added if the full text ever becomes quotable; none is asserted here on the
  strength of a secondary summary.

  What is not curated. There is no whole-organism model of the human genotype:
  the homozygous Dmxl2 null is embryonic lethal in mice, so the animal_models
  entry is the heterozygote, at low fidelity and with that stated. There are no biochemical markers, no datasets, no
  clinical trials and no environmental factors, because none are described in the
  DEE81 literature. Seizure semiology beyond the founding cohort's Ohtahara
  diagnosis and the one later focal-onset case is not curated, because the
  abstracts do not itemise it.
references:
- reference: PMID:31688942
  title: "Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course."
  findings: []
- reference: PMID:40180340
  title: "Neonate with developmental and epileptic encephalopathy 81 (DEE81): lessons learnt and future implications."
  findings: []
- reference: PMID:40646309
  title: "A heterotrimeric protein complex assembles the metazoan V-ATPase upon dissipation of proton gradients."
  findings: []
- reference: PMID:34249946
  title: "RAVE and Rabconnectin-3 Complexes as Signal Dependent Regulators of Organelle Acidification."
  findings: []
- reference: PMID:39273013
  title: "V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities."
  findings: []
- reference: PMID:30237576
  title: "Autozygome and high throughput confirmation of disease genes candidacy."
  findings: []
- reference: PMID:18469812
  title: "De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy."
  findings: []
- reference: PMID:26865513
  title: "STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy."
  findings: []
📚

References & Deep Research

References

8
PMID:31688942
Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course.
No top-level findings curated for this source.
PMID:40180340
Neonate with developmental and epileptic encephalopathy 81 (DEE81): lessons learnt and future implications.
No top-level findings curated for this source.
PMID:40646309
A heterotrimeric protein complex assembles the metazoan V-ATPase upon dissipation of proton gradients.
No top-level findings curated for this source.
PMID:34249946
RAVE and Rabconnectin-3 Complexes as Signal Dependent Regulators of Organelle Acidification.
No top-level findings curated for this source.
PMID:39273013
V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities.
No top-level findings curated for this source.
PMID:30237576
Autozygome and high throughput confirmation of disease genes candidacy.
No top-level findings curated for this source.
PMID:18469812
De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy.
No top-level findings curated for this source.
PMID:26865513
STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record notes

Scope. Only sources about the biallelic, recessive neurological phenotype are cited for disease claims. DMXL2 also causes autosomal dominant non-syndromic deafness DFNA71 and a polyendocrine and polyneuropathy syndrome, and the mouse and hair-cell literature on Dmxl2 is largely written against the deafness phenotype; none of it is used here to support a DEE81 claim. The DMXL2 mentions in Aromatase_Excess_Syndrome are a neighbouring-locus artefact - heterozygous 15q21.2 rearrangements that delete DMXL2 exons while creating a chimeric CYP19A1 transcript - and are not coverage of this disease. Evidence grading. PMID:31688942 is deliberately graded three ways, because it reports three kinds of study: the family genotypes, clinical course and MRI are HUMAN_CLINICAL; the fibroblast and cultured-neuron experiments are IN_VITRO; and the sentences that summarise DMXL2 function or define Ohtahara syndrome are OTHER, because they are background rather than results of this study. The Dmxl2-silenced hippocampal neurons are IN_VITRO and not MODEL_ORGANISM: they are a dissociated primary culture, not a whole animal. Three phenotypes are deliberately left unattached to the pathograph: hearing impairment, peripheral neuropathy and dysmorphic features. They are well attested clinically - the founding report names all three - but no source explains how loss of DMXL2 produces them, and DEE81 has no reported extraneural mechanism work at all. Drawing an edge from any existing node to them would be asserting a mechanism nobody has shown. The hair-cell work that would speak to the deafness is written against DFNA71 and is not used here for the reason given above. Deep-research cross-check. A falcon deep-research run (research/Developmental_And_Epileptic_Encephalopathy_81-deep-research-falcon.md, 19 citations) passed the NEC gate against MONDO:0032858 with DMXL2 the dominant gene at 49 mentions and no competing gene, and its content is DEE81-specific throughout - it separates the three DMXL2 diseases explicitly rather than blending them. Comparing it against this entry surfaced four things, all incorporated: the Falace 2024 V-ATPase review as the source for DMXL2's role in getting the pump onto synaptic vesicles, the mouse genetics (embryonic lethal null, macrocephalic heterozygote), the additional homozygous DMXL2 patient reported by Maddirevula et al., and the model-fidelity problem that follows from the lethal null. It also surfaced findings that could not be curated, and the reason is a cache limit rather than a judgement: the report reads the founding paper's full text, while references_cache/PMID_31688942.md is abstract-only. Brain 2019 is not deposited in PMC (checked), so there is no route to the full text through the reference fetcher, and an evidence item needs an exact quote from cached text. The uncurated findings are per-patient seizure semiology (tonic predominant, some myoclonic), hypotonia and quadriparesis in 6/6, simplified gyral pattern in 2/6, the specification of the deafness as sensorineural in 6/6, and the rescue of the fibroblast lysosomal phenotype by wild-type DMXL2 re-expression. Each is a real finding from the paper's results section and each should be added if the full text ever becomes quotable; none is asserted here on the strength of a secondary summary. What is not curated. There is no whole-organism model of the human genotype: the homozygous Dmxl2 null is embryonic lethal in mice, so the animal_models entry is the heterozygote, at low fidelity and with that stated. There are no biochemical markers, no datasets, no clinical trials and no environmental factors, because none are described in the DEE81 literature. Seizure semiology beyond the founding cohort's Ohtahara diagnosis and the one later focal-onset case is not curated, because the abstracts do not itemise it.

Address review on PR #10620: diagnosis section, HP term, pathograph joins, deep-research run · 2026-09-02T22:32:13Z · View source

Response to the CHANGES_REQUESTED review on PR #10620. Four blocking items; three complied with, one sub-item declined with reasons. 1. Pathograph disconnection. All twelve phenotypes and both treatments were isolated from the mechanism chain. Added edges: Neuronal Hyperexcitability and Hypersynchrony -> EEG with Burst Suppression; Neonatal-Onset Refractory Seizures -> Seizure, Focal-Onset Seizure, Epileptic Encephalopathy; Developmental Encephalopathy -> Profound Global Developmental Delay; Impaired Prenatal Brain Development -> Thin Corpus Callosum, Cerebral Hypomyelination; Progressive Brain Atrophy and Leukoencephalopathy -> Cerebral Atrophy, Leukoencephalopathy. Nine of twelve phenotypes are now linked. Bare node names, not phenotypes# prefixes. Three phenotypes are deliberately left unlinked: hearing impairment, peripheral neuropathy and dysmorphic features. No source explains how DMXL2 loss produces them and DEE81 has no extraneural mechanism work; an edge would assert a mechanism nobody has shown. Recorded in notes. DECLINED: target_mechanisms on Antiseizure Medication. TreatmentEffectEnum offers INHIBITS/ACTIVATES/MODULATES/BYPASSES/RESTORES and every value would claim an effect on the hyperexcitability node that the only cited evidence contradicts, since the seizures persisted. The enum has no value for an intended target that failed. Reasoning recorded in the treatment's notes. 2. Molecular Genetic Testing moved from treatments: to a new diagnosis: section - the reviewer was right and I had misread the sibling entry. Added Brain MRI and Electroencephalography diagnosis entries while there, both snippet-supported. 3. Deep research. The review skill does require a DR artifact for a new entry; verified at .claude/skills/dismech-pr-review/SKILL.md line 91. Ran falcon (601s, 19 citations). just preflight-dr PASS against MONDO:0032858, DMXL2 49 mentions, no competing gene. Report is DEE81-specific and separates the three DMXL2 diseases explicitly. Content-completeness cross-check produced four additions: Falace 2024 (PMID:39273013) as the source for DMXL2 putting the V-ATPase onto synaptic vesicles and for the mouse genetics; an animal_models entry for the Dmxl2 heterozygous mouse (PARTIALLY_RECAPITULATES, LOW fidelity) since the homozygous null is embryonic lethal; a HUMAN_MODEL_MISMATCH discussion recording that no whole-organism model of the human genotype can exist; and a KNOWLEDGE_GAP discussion on the additional homozygous DMXL2 patient of Maddirevula et al. (PMID:30237576), where the primary report calls the phenotype a possible distinct allelic disorder and Falace counts it as a DMXL2 DEE case. DR findings NOT curated, because references_cache/PMID_31688942.md is abstract-only and Brain 2019 is not in PMC (checked via the PMC ID converter): per-patient seizure semiology, hypotonia and quadriparesis 6/6, simplified gyral pattern 2/6, deafness specified as sensorineural 6/6, and the wild-type DMXL2 rescue of the fibroblast phenotype. All are results-section findings with no quotable cached text. Recorded in notes rather than asserted from a secondary summary. 4. HP:0000407 Sensorineural hearing impairment replaced with HP:0000365 Hearing impairment. The reviewer was right: the abstract says only deafness, and my note justified the narrower term by appeal to the DFNA71 literature this entry otherwise refuses to cite. Note rewritten to say the binding can be specialised if a DEE81 report gives audiological detail. The DR report does say sensorineural in 6/6 from the full text, which is further reason to expect specialisation later, but it is not quotable from the cache. Non-blocking suggestions taken: classifications block (NEUROLOGIC, GENETICS_ENVIRONMENT_DISEASE); differential_diagnoses with an Ohtahara-heterogeneity entry and STXBP1 encephalopathy, the latter discriminated on zygosity with a haploinsufficiency quote rather than on unsourced imaging claims; CL:0000540 added to the node conforming to the module. Validation after all edits: just validate exit 0 with 68/68 snippets verified, validate-terms, validate-disorders, check-duplicate-keys, check-entity-refs, check-causal-targets, check-snippet-grading, check-snippet-length, check-title-snippets, check-folded-hyphens, check-environmental-evidence, check-stubs all exit 0; 13484 targeted pytest tests pass. Uncited DOI reference caches created by the DR run's citation-validation pass were removed rather than committed; only PMID:39273013 and PMID:30237576, which the entry cites, are added.

Create: Developmental and Epileptic Encephalopathy 81 (MONDO:0032858, DMXL2) · 2026-09-02T21:40:04Z · View source

Claim #10616. entry_type DISEASE: MONDO:0032858 was bound nowhere in kb/, MONDO places DEE81 directly under genetic developmental and epileptic encephalopathy with no closer curated parent, and the KB already curates numbered DEEs as standalone Disease entries (DEE 50, 83, 84, 89, 116). The pathograph is specific enough to stand alone - a V-ATPase assembly failure, which no other curated entry models. Named Entity Confusion control. DMXL2 causes three distinct human diseases: recessive DEE81, dominant non-syndromic deafness DFNA71, and a polyendocrine-polyneuropathy syndrome. Gene-frequency preflight does not separate them, so separation was done by reading each candidate. The DEE81 clinical literature is exactly two papers - PMID:31688942 (Esposito, Brain 2019; three sibling pairs, three unrelated families) and PMID:40180340 (BMJ Case Rep 2025; one consanguineous neonate). Both were confirmed to be about the biallelic neurological phenotype. The two further references cited (PMID:40646309, PMID:34249946) are gene- and complex-function sources with no disease claim attached to them. The hair-cell and mouse-cochlea Dmxl2 literature (PMID:39147590, PMID:40118164) was found and deliberately not used: it is written against DFNA71, and DEE81 deafness is cited from Esposito instead. DMXL2 in Aromatase_Excess_Syndrome was checked and is a neighbouring-locus artefact - heterozygous 15q21.2 rearrangements deleting DMXL2 exons while creating a chimeric CYP19A1 transcript - not coverage. No deep-research run. The whole DEE81 clinical literature is two papers, both read in full abstract; a DR pass would have added retrieval risk across the three DMXL2 diseases without adding sources. Mechanism. Eleven pathophysiology nodes from biallelic DMXL2 loss of function through failed mRAVE-dependent V-ATPase assembly, branching into the endolysosomal/autophagic arm (patient fibroblasts) and the synaptic-vesicle arm, converging on hyperexcitability, seizures, developmental encephalopathy and progressive atrophy. Two nodes conform to epilepsy_excitation_inhibition_imbalance. Which arm actually generates the seizures is unresolved, so the two routes are curated as competing mechanistic_hypotheses groups (synaptic_vesicle_route, lysosomal_autophagy_route), both EMERGING, with the edges into hyperexcitability marked INDIRECT_UNKNOWN_INTERMEDIATES and opted into their group. A KNOWLEDGE_GAP discussion with a proposed experiment attaches to the three nodes involved. A second KNOWLEDGE_GAP records the three-disease allelic heterogeneity. Evidence grading. PMID:31688942 is graded three ways on purpose, per sentence: HUMAN_CLINICAL for family genotypes, clinical course and MRI; IN_VITRO for the fibroblast and cultured-neuron experiments; OTHER for the two sentences that are background (the DMXL2 function summary and the Ohtahara definition). The Dmxl2-silenced mouse hippocampal neurons are IN_VITRO, not MODEL_ORGANISM: a dissociated primary culture is not a whole animal, so they are in experimental_models as PRIMARY_CELL_CULTURE and there is no animal_models section. Fatal outcome (five of six died within nine years) is in progression:, not phenotypes:, because HPO files death in infancy/childhood under clinical course. Frequencies. OBLIGATE is asserted only where the source says all patients. Cerebral atrophy and leukoencephalopathy carry no frequency because their denominator is the three patients with follow-up scans, not the cohort; focal-onset seizure carries none because it rests on one case. Every ontology term was resolved through OLS4 and label-checked against the API response. HP:0007260 was rejected during that check: it is Type II lissencephaly, not a hypomyelination term; HP:0006808 Cerebral hypomyelination is the correct one. Validation: just validate (exit 0, 48/48 snippets verified), validate-terms (exit 0), check-duplicate-keys, check-entity-refs, check-causal-targets, check-snippet-length, check-title-snippets, check-environmental-evidence, check-folded-hyphens, check-stubs all exit 0.

Falcon ▸
Developmental and Epileptic Encephalopathy 81 (DEE81): Disease-Characteristics Report
Edison Scientific Literature 19 citations 2026-09-02T15:17:40.837205

Developmental and Epileptic Encephalopathy 81 (DEE81): Disease-Characteristics Report

Executive summary and evidence limits

Developmental and epileptic encephalopathy 81 (DEE81) is an exceptionally rare, autosomal-recessive neurodevelopmental disorder caused by biallelic pathogenic variants in DMXL2. The defining report described six children—three sibling pairs from three unrelated families—with neonatal-onset Ohtahara syndrome, persistent suppression-burst EEG, profound developmental failure, hypomyelination, progressive cerebral volume loss, sensorineural deafness, and high childhood mortality. The mechanistic lesion is loss of rabconnectin-3α/DMXL2 function, disrupting V-ATPase regulation, endolysosomal homeostasis, autophagy, neurite development, and synapse formation. The evidence base remains dominated by this small 2019 case series; therefore, frequencies below are descriptive of that cohort, not population estimates. (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 5-6)

The principal primary source is Esposito et al., Brain, published December 2019, PMID 31688942, DOI 10.1093/brain/awz326. Its abstract states: “Impaired lysosomal function and autophagy caused by biallelic DMXL2 mutations affect neuronal development and synapse formation and result in Ohtahara syndrome with profound developmental impairment and reduced life expectancy.” (esposito2019biallelicdmxl2mutations pages 1-2, OpenTargets Search: -DMXL2)

Domain DEE81 evidence snapshot Evidence status
Identity Developmental and epileptic encephalopathy 81 (DEE81); OMIM 618663; severe progressive Ohtahara/early-infantile DEE phenotype. A disease-specific MONDO, Orphanet, ICD-10/11, or MeSH identifier was not established in the retrieved evidence. Human disease-level evidence (esposito2019biallelicdmxl2mutations pages 1-2, OpenTargets Search: -DMXL2)
Causal gene / inheritance DMXL2 (Dmx-like 2; rabconnectin-3α); biallelic loss-of-function or severe hypomorphic variants; autosomal recessive. Parents in the three foundational families were heterozygous and clinically unaffected. Human segregation and functional evidence (esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 13-14)
Known DEE81 variants Family 1: compound heterozygous c.5135C>T (p.Ala1712Val) and c.4478C>G (p.Ser1493*); Family 2: homozygous c.4478C>A (p.Ser1493*); Family 3: homozygous c.7518-1G>A, causing exon-31 skipping and p.Trp2507Argfs*4 (also rendered p.Trp2508Argfs*4 in one passage). All were absent from gnomAD in the original report. Human molecular evidence (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 5-6)
Foundational cohort size 6 affected children, comprising 3 sibling pairs from 3 unrelated families. No sufficiently large DEE81-specific natural-history cohort was identified. Human case series (esposito2019biallelicdmxl2mutations pages 1-2)
Onset, EEG, and seizures Manifestation began on the first day or first days of life. All six had persistent/continuous suppression-burst EEG consistent with Ohtahara syndrome. Seizures were predominantly tonic, less often myoclonic, with occasional focal seizures; epilepsy was described as intractable. Exact patient-level seizure frequencies and treatment-response rates are unknown. Human clinical evidence (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 5-6)
Development and motor function 6/6 had profound developmental impairment, hypotonia, and quadriparesis; 0/6 acquired developmental, communicative, or motor skills after birth. Human clinical evidence (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 5-6)
Brain MRI Early MRI showed thin/hypoplastic corpus callosum and hypomyelination in 6/6. Two children had a simplified gyral pattern. Serial MRI in 3 patients, performed 9–21 months later, showed progressive grey- and white-matter volume loss/brain shrinkage with leukoencephalopathy. Human imaging evidence (esposito2019biallelicdmxl2mutations pages 8-10, esposito2019biallelicdmxl2mutations pages 5-6)
Extra-neurologic findings Sensorineural hearing loss and dysmorphic features occurred in 6/6. Mild peripheral polyneuropathy occurred in 4/4 evaluated children from Families 1 and 2; nerve-conduction testing was not reported for Family 3. Respiratory/systemic complications contributed to deaths. Detailed organ-specific frequencies and standardized quality-of-life measurements are unknown. Human clinical evidence (esposito2019biallelicdmxl2mutations pages 5-6)
Mortality / prognosis 5/6 (83%) died before age 9; one child was alive at 15 months at reporting. Cause-specific survival curves, median survival, and treated-versus-untreated life expectancy are unknown. Human case-series evidence (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 5-6)
Mechanism DMXL2 deficiency disrupts V-ATPase regulation and endolysosomal homeostasis, producing defective degradation and autophagy: reduced LC3/LC3-II, p62 and polyubiquitinated-protein accumulation, and abnormal autolysosomes. Patient fibroblast abnormalities were rescued by wild-type DMXL2. Dmxl2-silenced mouse hippocampal neurons showed impaired neurite growth and synaptic loss; the link from these cellular defects to seizures is strongly supported but partly inferential. Human cells, rescue experiments, and mouse-neuron model (esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 10-11, falace2024vatpasedysfunctionin pages 8-9, esposito2019biallelicdmxl2mutations pages 11-12)
Diagnostics Molecular confirmation requires identification of pathogenic/likely pathogenic variants on both DMXL2 alleles with parental phasing. Exome/genome sequencing or a comprehensive epilepsy/DEE panel with copy-number analysis is appropriate; EEG, brain MRI, hearing assessment, developmental evaluation, and neuropathy surveillance define extent. No validated DEE81-specific biochemical biomarker or formal diagnostic criteria are known. Disease-specific discovery plus general epilepsy-genomics evidence (esposito2019biallelicdmxl2mutations pages 1-2, guerrini2023developmentalandepileptic pages 3-4, grew2024yieldandutility pages 1-2)
Treatment / trials No disease-modifying therapy, genotype-specific drug, or relevant registered DMXL2/DEE81 interventional trial was identified. Care is supportive and phenotype-directed; no reproducible DEE81-specific antiseizure-drug response rate is available. V-ATPase, lysosomal-acidification, and autophagy modulation remain preclinical therapeutic concepts. Evidence gap and mechanistic review (falace2024vatpasedysfunctionin pages 8-9)
Epidemiology Population prevalence, incidence, carrier frequency, sex ratio, founder effects, and geographic-risk estimates are unknown. Published evidence is limited principally to three families, including consanguineous Israeli-Arab and Turkish families and a non-consanguineous Italian-Brazilian family; this does not establish population enrichment. Very limited human case-series evidence (esposito2019biallelicdmxl2mutations pages 5-6)

Table: A compact evidence map of DMXL2-related DEE81, separating quantified observations from currently unknown epidemiologic, diagnostic, and therapeutic information.

1. Disease information

Definition

DEE81 is a severe early-infantile developmental and epileptic encephalopathy in which a primary prenatal/neonatal neurodevelopmental defect and severe epileptic activity both contribute to neurological dysfunction. In the original cohort, disease was recognizable as Ohtahara syndrome, now generally termed early-infantile developmental and epileptic encephalopathy with suppression-burst. DEEs more broadly are defined by early, often severe seizures and EEG abnormalities superimposed on developmental impairment, with developmental pathology and epileptic activity potentially making independent and interacting contributions. (esposito2019biallelicdmxl2mutations pages 1-2, guerrini2023developmentalandepileptic pages 3-4)

Identifiers and names

  • Preferred name: Developmental and epileptic encephalopathy 81
  • Abbreviation: DEE81
  • OMIM: 618663
  • Causal gene: DMXL2, OMIM gene 612186
  • Synonyms: early infantile epileptic encephalopathy 81; EIEE81; DMXL2-related developmental and epileptic encephalopathy; DMXL2-related Ohtahara syndrome; progressive Ohtahara syndrome due to biallelic DMXL2 variants.
  • MONDO: a disease-specific DEE81 identifier was not established in the retrieved evidence. Broader applicable concepts include genetic developmental and epileptic encephalopathy (MONDO:0100062) and early-infantile DEE (MONDO:0800491); these should not be substituted automatically for a DEE81-specific identifier. Open Targets links DMXL2 to both broader concepts. (OpenTargets Search: -DMXL2)
  • Orphanet, MeSH: no specific DEE81 entries were verified.
  • ICD-10/ICD-11: no gene-specific code exists in the evidence reviewed; coding ordinarily uses epilepsy/epileptic-encephalopathy, developmental-disability, hearing-loss, and other manifestation codes.

The foundational evidence is aggregated from published patient-level clinical, segregation, imaging, and functional data, not from an EHR-derived population cohort. Database records such as OMIM and Open Targets are disease-level aggregations. (esposito2019biallelicdmxl2mutations pages 1-2, OpenTargets Search: -DMXL2)

2. Etiology, risk, and protective factors

Cause

The primary cause is germline biallelic DMXL2 dysfunction, predominantly complete or near-complete loss of function. Reported DEE81 alleles were absent from gnomAD in the original publication and segregated with disease under an autosomal-recessive model. Heterozygous parents were clinically unaffected. (esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 13-14)

Genetic risk factors

The established risk state is inheritance of pathogenic variants on both alleles. Consanguinity increases the probability that both parents carry the same rare allele but is not required: two foundational families were consanguineous, whereas the Italian-Brazilian family was not. For carrier parents, the standard Mendelian risk for each pregnancy is 25% affected, 50% carrier, and 25% unaffected/non-carrier, assuming correctly phased fully penetrant alleles.

DMXL2 has allelic heterogeneity. Biallelic severe loss causes DEE81, whereas a biallelic in-frame deletion retaining approximately 30% transcript was associated with a comparatively milder polyendocrine-polyneuropathy syndrome. Heterozygous variants or deletions have been reported with dominant hearing loss or variably penetrant neurodevelopmental phenotypes; these should not be conflated with recessive DEE81. (esposito2019biallelicdmxl2mutations pages 2-3, esposito2019biallelicdmxl2mutations pages 13-14)

Environmental, infectious, lifestyle, and protective factors

No environmental toxin, infection, diet, lifestyle exposure, or gene–environment interaction is established as causal for DEE81. No protective DMXL2 allele or environmental protective factor has been reported. Fever, sleep deprivation, infection, and medication nonadherence may generally precipitate seizures in epilepsy, but no DEE81-specific quantitative evidence was found. Vaccination is not causal; routine immunization remains appropriate unless individualized clinical considerations dictate otherwise.

3. Phenotypes

Observed frequencies refer to the original six-patient cohort.

  • Neonatal-onset epilepsy/Ohtahara syndrome: 6/6; predominantly tonic seizures, less commonly myoclonic and occasional focal seizures; severe and persistent. Suggested HPO: Seizure HP:0001250, Tonic seizure HP:0032792, Myoclonic seizure HP:0002123, Focal-onset seizure HP:0007359, EEG with suppression-burst pattern HP:0010851. (esposito2019biallelicdmxl2mutations pages 5-6)
  • Persistent suppression-burst EEG: 6/6, beginning in the first days of life and remaining continuous during follow-up; wake and sleep were difficult to distinguish. This is an objective electrophysiological sign rather than a symptom. (esposito2019biallelicdmxl2mutations pages 5-6)
  • Profound global developmental impairment: 6/6; none acquired developmental, communicative, or motor skills after birth. Suggested HPO: Global developmental delay HP:0001263, Profound global developmental delay HP:0012736, Absent speech HP:0001344. The effect on daily function is catastrophic, implying complete dependence for activities of daily living, although no EQ-5D, SF-36, PROMIS, or caregiver-burden study exists. (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 5-6)
  • Hypotonia and quadriparesis: 6/6, severe and persistent. HPO: Muscular hypotonia HP:0001252, Quadriparesis HP:0002273. (esposito2019biallelicdmxl2mutations pages 5-6)
  • Sensorineural hearing loss: 6/6. HPO: Sensorineural hearing impairment HP:0000407. Formal severity distributions were not available. (esposito2019biallelicdmxl2mutations pages 5-6)
  • Peripheral polyneuropathy: 4/4 evaluated children in Families 1 and 2; Family 3 was not assessed electrophysiologically. HPO: Peripheral neuropathy HP:0009830, potentially Sensorimotor neuropathy HP:0007141. (esposito2019biallelicdmxl2mutations pages 5-6)
  • Brain hypomyelination and thin/hypoplastic corpus callosum: 6/6 on early MRI. HPO: Hypomyelination HP:0003429, Thin corpus callosum HP:0002079. (esposito2019biallelicdmxl2mutations pages 8-10, esposito2019biallelicdmxl2mutations pages 5-6)
  • Simplified gyral pattern: 2/6, frontal-limited in one and diffuse with frontal predominance in another. HPO: Simplified gyral pattern HP:0009879. (esposito2019biallelicdmxl2mutations pages 5-6)
  • Progressive cerebral and white-matter volume loss/leukoencephalopathy: observed in all three with serial MRI 9–21 months later. HPO: Cerebral atrophy HP:0002059, Leukoencephalopathy HP:0002352, Ventriculomegaly HP:0002119 where present. (esposito2019biallelicdmxl2mutations pages 8-10, esposito2019biallelicdmxl2mutations pages 5-6)
  • Dysmorphic features: 6/6, but no sufficiently specific recurrent gestalt was established. HPO annotation should be patient-specific rather than assigning a generic dysmorphism term. (esposito2019biallelicdmxl2mutations pages 5-6)
  • Laboratory/muscle findings: muscle coenzyme-Q concentration was normal; one patient had abundant intramuscular lipid droplets. This isolated observation is not a validated biomarker. (esposito2019biallelicdmxl2mutations pages 5-6)

No systematic behavioral phenotype, pain assessment, sleep measure, laboratory signature, or formal quality-of-life dataset is available.

4. Genetic and molecular information

Gene: DMXL2 (Dmx-like 2/rabconnectin-3α); Ensembl ENSG00000104093. HGNC and NCBI Gene numerical identifiers were not verified in the retrieved evidence. The protein contains 16 conserved WD40 domains and a central domain homologous to yeast Rav1p. It is brain enriched, abundant at synaptic terminals, and participates in complexes governing V-ATPase assembly and activity. (OpenTargets Search: -DMXL2, falace2024vatpasedysfunctionin pages 8-9, esposito2019biallelicdmxl2mutations pages 2-3)

Foundational variants

  1. c.5135C>T, p.(Ala1712Val) in trans with c.4478C>G, p.(Ser1493Ter) in Family 1.
  2. Homozygous c.4478C>A, p.(Ser1493Ter) in Family 2.
  3. Homozygous c.7518-1G>A, disrupting the exon-31 splice acceptor, causing exon skipping and a frameshift reported as p.(Trp2507ArgfsTer4); one passage renders the residue as Trp2508. Transcript-specific HGVS normalization is therefore advisable before database ingestion. (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 5-6)

The nonsense and splice variants are loss-of-function alleles. The p.Ala1712Val missense allele occurred with a truncating allele and was supported by segregation and the near-absence of DMXL2 in patient cells. All foundational variants were absent from gnomAD at publication. They are constitutional germline variants; no somatic DEE81 mechanism is known. Patient fibroblasts showed nearly absent protein, and wild-type DMXL2 re-expression rescued the LysoTracker phenotype, providing strong functional support. (esposito2019biallelicdmxl2mutations pages 6-7)

No validated modifier genes, protective variants, recurrent structural rearrangement specific to DEE81, disease-associated episignature, or clinically actionable pharmacogenomic association is known. Rare heterozygous DMXL2-spanning CNVs have been associated with broader neurodevelopmental susceptibility, but they are not established causes of the classic recessive DEE81 phenotype. (esposito2019biallelicdmxl2mutations pages 2-3)

5. Environmental information

DEE81 is a Mendelian genetic disease. No toxin, radiation, pollution, occupational exposure, smoking, diet, alcohol, exercise pattern, or infectious organism has been implicated in disease initiation. Environmental factors may influence seizure burden or complications nonspecifically but do not explain the core disorder. Accordingly, CTD-style chemical–disease or pathogen annotations would presently be speculative.

6. Mechanism and pathophysiology

Ordered causal chain

  1. Biallelic severe DMXL2 variants lead to absent or markedly reduced rabconnectin-3α.
  2. DMXL2 deficiency leads to impaired assembly/trafficking and activity of V-ATPase on synaptic and endolysosomal membranes.
  3. Defective V-ATPase regulation leads to abnormal organellar acidification and endosomal/lysosomal homeostasis.
  4. Endolysosomal dysfunction results in slowed cargo degradation and defective autophagic flux, demonstrated by reduced LC3/LC3-II, p62 and polyubiquitinated-protein accumulation, reduced endolysosomal markers, and abnormal autolysosomal ultrastructure.
  5. Defective neuronal clearance and vesicle physiology lead to impaired neurite elongation and loss of synaptic contacts in Dmxl2-silenced mouse hippocampal neurons.
  6. Impaired prenatal circuit formation and synaptic maintenance are inferred to lead to neonatal suppression-burst EEG, severe seizures, and absent developmental acquisition.
  7. A parallel branch of neural vulnerability leads to hypomyelination, corpus-callosum hypoplasia, deafness, and peripheral neuropathy; continued lysosomal/autophagic failure is inferred to result in progressive cerebral shrinkage, leukoencephalopathy, systemic vulnerability, and premature death. (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 6-7, falace2024vatpasedysfunctionin pages 8-9, esposito2019biallelicdmxl2mutations pages 11-12)

DMXL2/rabconnectin-3α interacts with synaptic-vesicle Rab3A-associated machinery and participates in V-ATPase incorporation into synaptic vesicles through its Rav1p-homologous region. V-ATPase-driven proton transport is required for organelle acidification, endocytic degradation, autophagy, and neurotransmitter-vesicle biology. The 2024 expert review emphasizes that postmitotic neurons are uniquely vulnerable to lysosomal dyshomeostasis and identifies V-ATPase dysfunction as a mechanistic bridge among early DEE, neurodevelopmental disorders, and neurodegeneration. (falace2024vatpasedysfunctionin pages 8-9)

Experimental evidence: patient fibroblasts showed increased LysoTracker signal, reduced EEA1 and LAMP1, slowed EGFR and dextran degradation, decreased LC3-II/LC3-I, p62 accumulation, polyubiquitinated-protein accumulation, and abnormal vacuoles. Re-expression of wild-type DMXL2 rescued the acidic-organelle phenotype. Dmxl2-silenced mouse hippocampal neurons recapitulated lysosomal/autophagic abnormalities and showed reduced neurite complexity and synaptic contacts, especially excitatory dendritic connections. (esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 10-11, esposito2019biallelicdmxl2mutations pages 5-6, esposito2019biallelicdmxl2mutations pages 11-12)

No DEE81-specific human brain single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or integrated multi-omic dataset was found. The isolated muscle lipid-droplet observation is insufficient to define a lipidomic signature.

Suggested GO biological processes: vacuolar acidification (GO:0007035), autophagy (GO:0006914), macroautophagy (GO:0016236), endosomal transport (GO:0016197), lysosomal transport (GO:0007041), synapse organization (GO:0050808), neuron projection development (GO:0031175), and regulation of synaptic vesicle exocytosis (GO:2000300). Suggested cellular components include lysosome (GO:0005764), endosome (GO:0005768), autophagosome (GO:0005776), synaptic vesicle (GO:0008021), and V-type proton-transporting ATPase complex (GO:0016471).

Suggested Cell Ontology terms: neuron (CL:0000540), central nervous system neuron (CL:0000117), hippocampal neuron where experimentally relevant, oligodendrocyte (CL:0000128, inferred from hypomyelination), Schwann cell (CL:0002573, inferred from peripheral neuropathy), and inner-ear sensory hair cell (CL:0000202, inferred from sensorineural hearing loss).

7. Anatomical structures affected

The nervous system is primary: cerebral cortex and white matter, corpus callosum, synaptic networks, peripheral nerves, and auditory pathways/inner ear. The MRI phenotype is bilateral/diffuse rather than consistently lateralized. Suggested UBERON annotations are brain UBERON:0000955, cerebral cortex UBERON:0000956, white matter UBERON:0002316, corpus callosum UBERON:0002336, hippocampus UBERON:0002421 for the experimental model, peripheral nervous system UBERON:0000010, and inner ear UBERON:0001846. (esposito2019biallelicdmxl2mutations pages 8-10, esposito2019biallelicdmxl2mutations pages 5-6)

At the subcellular level, lysosomes, endosomes, autophagosomes/autolysosomes, synaptic vesicles, axons/neurites, and synapses are implicated. No consistent primary cardiovascular, renal, hepatic, endocrine, immune, or skeletal-organ phenotype has been established for classic DEE81. Endocrine disease belongs chiefly to a distinct, partially residual-function DMXL2 phenotype. (esposito2019biallelicdmxl2mutations pages 2-3)

8. Temporal development

The classic course begins on day 1 or within the first days of life, implying prenatal pathogenesis with neonatal clinical expression. Seizures and suppression-burst EEG are chronic and severe rather than a self-limited neonatal epilepsy. Developmental skills fail to emerge, and neurological disability remains profound. Early MRI already shows hypomyelination and callosal hypoplasia; serial imaging over 9–21 months can show progressive grey- and white-matter loss and leukoencephalopathy. Thus, DEE81 combines a congenital developmental encephalopathy with superimposed progressive neurodegeneration. (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 5-6)

No validated stages or remission pattern exist. The neonatal period is the critical diagnostic window, but whether very early seizure suppression modifies development is unknown. The disorder is lifelong in survivors.

9. Inheritance and population

Inheritance is autosomal recessive. Available segregation suggests high penetrance for the severe biallelic genotypes, but the sample is too small for a formal estimate. Expressivity may depend on residual DMXL2 function; complete/near-complete loss produces severe DEE, whereas residual transcript has been associated with a milder multisystem phenotype. Anticipation is not expected. Parental germline mosaicism has not been demonstrated for DEE81, although it remains a generic residual-risk consideration after an apparently de novo variant. (esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 13-14)

Prevalence, incidence, carrier frequency, sex ratio, founder effects, and ethnic/geographic enrichment are unknown. The initial families were Italian-Brazilian, Israeli Arab, and Turkish; two involved first-cousin parents. These observations demonstrate worldwide occurrence and a role for consanguinity but not population-specific enrichment. Five deaths among six reported children must not be interpreted as a population mortality rate without larger ascertainment-unbiased cohorts. (esposito2019biallelicdmxl2mutations pages 5-6)

For context, a 2023 authoritative review estimated that next-generation sequencing detects pathogenic single-gene variants in approximately 30–50% of DEEs overall and that recessive variants account for 11–38% in reported cohorts; these figures are not DEE81-specific. (guerrini2023developmentalandepileptic pages 3-4)

10. Diagnostics

Clinical recognition

Suspect DEE81 in a neonate with tonic seizures, persistent suppression-burst EEG, profound hypotonia, absent developmental acquisition, sensorineural hearing loss, and MRI showing hypomyelination with a thin corpus callosum—especially with consanguinity, similarly affected siblings, or progressive cerebral volume loss.

Recommended evaluation is:

  1. Prolonged video-EEG, including sleep and wake sampling.
  2. Brain MRI with age-appropriate myelination assessment; repeat MRI when progression is clinically relevant.
  3. Comprehensive neurological and developmental assessment.
  4. Audiology, ideally auditory brainstem responses in infancy.
  5. Peripheral-nerve examination and nerve-conduction studies where feasible.
  6. Swallowing, nutrition, respiratory, orthopedic, vision, and palliative-care assessments according to manifestations.
  7. Genetic counseling and parental segregation studies. (esposito2019biallelicdmxl2mutations pages 8-10, esposito2019biallelicdmxl2mutations pages 5-6)

Molecular testing

Trio WES or WGS is preferred because early-infantile DEE is genetically heterogeneous. A comprehensive epilepsy/DEE panel is acceptable if it includes DMXL2, full coding/splice coverage, and deletion/duplication analysis. Confirm candidate variants by an orthogonal method and phase them in the parents. WGS may identify intronic, regulatory, structural, or copy-number lesions missed by WES. RNA studies from accessible cells can test suspected splice variants; fibroblast DMXL2 expression, endolysosomal markers, or LysoTracker rescue are research-level functional assays, not validated clinical diagnostics. (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 6-7, guerrini2023developmentalandepileptic pages 3-4)

Routine karyotyping, FISH, mitochondrial testing, or repeat-expansion testing is not specifically indicated after convincing biallelic DMXL2 findings, although CMA or genome-wide CNV analysis remains useful in unsolved DEE. There are no standardized DEE81 biochemical criteria, newborn screen, liquid biopsy, or validated metabolomic/proteomic biomarker.

Recent real-world evidence supports broad genomic testing: a 2024 pediatric study found pathogenic variants in 11/65 (16.9%) routine epilepsy panels, whereas a separate 142-family cohort obtained molecular diagnoses in 74/142 (52%), with therapeutic implications in 38/74 diagnosed families. These are general epilepsy data, not DMXL2-specific yields. (majethia2024geneticandphenotypic pages 1-3, grew2024yieldandutility pages 1-2)

Differential diagnosis: other suppression-burst/early-infantile DEEs, including STXBP1-, KCNQ2-, SCN2A-, KCNT1-, DNM1-, WWOX-, BRAT1-, DOCK7-, and ATP6V1A-related disorders; mitochondrial/metabolic epileptic encephalopathies; structural cortical malformations; congenital infections; and other lysosomal/autophagy or V-ATPase disorders. The combination of deafness, neuropathy, hypomyelination/callosal thinning, progression, and biallelic DMXL2 variants distinguishes DEE81.

11. Outcome and prognosis

Prognosis in the foundational cohort was extremely poor: none of six children acquired motor, communicative, or other developmental skills, and five died before nine years of age from respiratory or systemic complications. One child remained alive at 15 months when reported. No Kaplan–Meier survival estimate, median life expectancy, prognostic biomarker, or treated-versus-untreated comparison exists. (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 5-6)

Expected morbidity includes medically complex epilepsy, profound lifelong disability, immobility/quadriparesis, feeding and aspiration risk, respiratory vulnerability, deafness, neuropathy, contractures, and complete caregiver dependence. Serial MRI progression and null protein expression may indicate severe disease, but neither is validated as an individual prognostic biomarker. Formal quality-of-life data are unavailable.

12. Treatment

No disease-modifying or DMXL2-targeted therapy is approved, no reproducible genotype-specific antiseizure-medication response has been published, and no relevant registered DMXL2/DEE81 interventional trial was identified. Treatment is therefore individualized and supportive.

  • Epilepsy: specialist management using antiseizure medications appropriate to neonatal/tonic seizures and EEG evolution; consider ketogenic diet, hormonal therapy if spasms develop, and other refractory-epilepsy strategies according to standard practice. Evidence for any one option in DEE81 is absent.
  • Respiratory and feeding care: swallowing evaluation, aspiration prevention, nutrition support, airway-clearance planning, and gastrostomy when clinically indicated.
  • Rehabilitation: physical, occupational, speech/communication, positioning, orthopedic, and contracture-prevention services, recognizing limited developmental potential in reported null genotypes.
  • Hearing: audiologic monitoring and hearing-assistive interventions where benefit is feasible.
  • Neuropathy and immobility: pain surveillance, orthotics, pressure-injury prevention, and mobility equipment.
  • Psychosocial and palliative care: early family support, respite, goals-of-care discussions, and pediatric palliative involvement are appropriate given the severe natural history.

Suggested NCIt intervention concepts include Anticonvulsant Therapy (NCIT:C64276), Ketogenic Diet, Physical Therapy, Occupational Therapy, Speech and Language Therapy, Gastrostomy, Hearing Aid, Genetic Counseling, and Palliative Care; local terminology services should verify exact current NCIt identifiers before ingestion.

Restoration of DMXL2 rescued lysosomal abnormalities in patient fibroblasts, making gene replacement conceptually attractive. Modulating V-ATPase assembly, lysosomal acidification, or autophagy is also mechanistically plausible, but the 2024 expert review treats these as emerging preclinical opportunities—not treatments ready for patients. Nonspecific autophagy activation could be harmful and should not be attempted outside research. (esposito2019biallelicdmxl2mutations pages 6-7, falace2024vatpasedysfunctionin pages 8-9)

13. Prevention

There is no lifestyle, environmental, drug, or vaccine-based primary prevention. Effective prevention is reproductive and diagnostic:

  • Offer molecular confirmation and genetic counseling to affected families.
  • Once familial variants are known, offer carrier testing to adult relatives, prenatal diagnosis by chorionic-villus sampling or amniocentesis, and preimplantation genetic testing for monogenic disease.
  • For future pregnancies without prior testing, early trio sequencing is appropriate if fetal/neonatal neurological findings emerge.
  • Population newborn or carrier screening is not supported because prevalence and carrier frequency are unknown.
  • Secondary prevention consists of rapid recognition and treatment of neonatal seizures and early management of feeding, respiratory, hearing, and orthopedic complications; whether seizure control changes the underlying developmental trajectory is unknown.
  • Tertiary prevention includes aspiration precautions, immunization against routine respiratory pathogens, contracture and pressure-injury prevention, nutrition optimization, and emergency seizure plans.

14. Other species and natural disease

No naturally occurring veterinary disease equivalent, affected breed, zoonotic transmission, or cross-species infectious susceptibility is known. DEE81 is noninfectious and has no zoonotic potential.

DMXL2 is evolutionarily conserved, as shown by its Rav1p-related domain and conserved role in V-ATPase regulation. Mus musculus (NCBI Taxon 10090) Dmxl2 is the principal experimentally relevant ortholog; rat hippocampal neurons have also been used in mechanistic work. Exact NCBI Gene identifiers for orthologs were not verified in the retrieved evidence. (falace2024vatpasedysfunctionin pages 8-9, esposito2019biallelicdmxl2mutations pages 2-3)

15. Model organisms and experimental systems

  • Patient-derived fibroblasts: the strongest human cellular model. They reproduce absent protein, endolysosomal and autophagic defects, and permit rescue by wild-type DMXL2. Limitation: fibroblasts do not reproduce neuronal network activity, myelination, or seizures. (esposito2019biallelicdmxl2mutations pages 6-7, esposito2019biallelicdmxl2mutations pages 10-11)
  • Primary mouse hippocampal neurons with Dmxl2 shRNA: reproduce altered lysosomal/autophagy markers, reduced neurite complexity, and synaptic loss. Because silenced cells were embedded in a largely unaffected network, the phenotype supports a cell-autonomous component. Limitations include acute knockdown rather than germline human alleles and absence of a whole-animal seizure phenotype. (esposito2019biallelicdmxl2mutations pages 8-10, esposito2019biallelicdmxl2mutations pages 10-11, esposito2019biallelicdmxl2mutations pages 11-12)
  • Mouse genetics: complete Dmxl2 loss is reported as embryonically lethal; heterozygous mice show macrocephaly and corpus-callosum dysplasia. This demonstrates developmental dosage sensitivity but does not fully model recessive human DEE81. (falace2024vatpasedysfunctionin pages 8-9)
  • Needed models: patient iPSC-derived excitatory and inhibitory neurons, oligodendrocytes, auditory cells, cerebral organoids, and knock-in mice carrying the human alleles would enable testing of network excitability, myelination, developmental timing, and gene-replacement strategies. These are research recommendations, not currently demonstrated DEE81 resources.

Current expert assessment

The 2024 V-ATPase review places DMXL2 among brain-enriched V-ATPase accessory proteins whose disruption unifies neurodevelopmental failure with progressive neuronal dysfunction. The best-supported interpretation is therefore not simply “epilepsy causing delay,” but a congenital disorder of organelle acidification and autophagy that directly impairs brain wiring, with epileptic activity adding further dysfunction. The decisive evidence consists of recessive segregation, absence of DMXL2 protein, reproducible lysosomal/autophagic abnormalities, rescue by wild-type DMXL2, and concordant neuronal knockdown phenotypes. Nevertheless, the clinical evidence remains only six foundational patients; prevalence, full allelic spectrum, treatment response, and long-term variability require international case aggregation and prospective natural-history study. (esposito2019biallelicdmxl2mutations pages 6-7, falace2024vatpasedysfunctionin pages 8-9)

Key publications

  1. Esposito A, et al. Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course. Brain. December 2019;142:3876–3891. PMID: 31688942. DOI: 10.1093/brain/awz326. Primary human case series, patient-cell functional studies, and mouse-neuron experiments. (esposito2019biallelicdmxl2mutations pages 1-2, esposito2019biallelicdmxl2mutations pages 6-7)
  2. Guerrini R, et al. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiological Reviews. January 2023;103:433–513. DOI: 10.1152/physrev.00063.2021. Authoritative general DEE review. (guerrini2023developmentalandepileptic pages 3-4)
  3. Falace A, et al. V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities. Cells. August 2024;13:1441. DOI: 10.3390/cells13171441. Recent mechanistic review covering DMXL2 and translational directions. (falace2024vatpasedysfunctionin pages 8-9)
  4. Majethia P, et al. Genetic and phenotypic landscape of pediatric-onset epilepsy in 142 Indian families. Clinical Genetics. February 2024. DOI: 10.1111/cge.14495. Contemporary evidence for the diagnostic and therapeutic utility of genomic testing, not DEE81-specific. (majethia2024geneticandphenotypic pages 1-3)
  5. Grew EC, et al. Yield and Utility of Routine Epilepsy Panel Genetic Testing Among Young Patients With Seizures. Journal of Child Neurology. March 2024. DOI: 10.1177/08830738241240516. General pediatric epilepsy-testing implementation study. (grew2024yieldandutility pages 1-2)

References

  1. (esposito2019biallelicdmxl2mutations pages 1-2): Alessandro Esposito, Antonio Falace, Matias Wagner, Moran Gal, Davide Mei, Valerio Conti, Tiziana Pisano, Davide Aprile, Maria Sabina Cerullo, Antonio De Fusco, Silvia Giovedì, Annette Seibt, Daniella Magen, Tilman Polster, Ayelet Eran, Sarah L Stenton, Chiara Fiorillo, Sarit Ravid, Ertan Mayatepek, Hava Hafner, Saskia Wortmann, Erez Y Levanon, Carla Marini, Hanna Mandel, Fabio Benfenati, Felix Distelmaier, Anna Fassio, and Renzo Guerrini. Biallelic dmxl2 mutations impair autophagy and cause ohtahara syndrome with progressive course. Brain : a journal of neurology, 142:3876-3891, Dec 2019. URL: https://doi.org/10.1093/brain/awz326, doi:10.1093/brain/awz326. This article has 51 citations.

  2. (esposito2019biallelicdmxl2mutations pages 6-7): Alessandro Esposito, Antonio Falace, Matias Wagner, Moran Gal, Davide Mei, Valerio Conti, Tiziana Pisano, Davide Aprile, Maria Sabina Cerullo, Antonio De Fusco, Silvia Giovedì, Annette Seibt, Daniella Magen, Tilman Polster, Ayelet Eran, Sarah L Stenton, Chiara Fiorillo, Sarit Ravid, Ertan Mayatepek, Hava Hafner, Saskia Wortmann, Erez Y Levanon, Carla Marini, Hanna Mandel, Fabio Benfenati, Felix Distelmaier, Anna Fassio, and Renzo Guerrini. Biallelic dmxl2 mutations impair autophagy and cause ohtahara syndrome with progressive course. Brain : a journal of neurology, 142:3876-3891, Dec 2019. URL: https://doi.org/10.1093/brain/awz326, doi:10.1093/brain/awz326. This article has 51 citations.

  3. (esposito2019biallelicdmxl2mutations pages 5-6): Alessandro Esposito, Antonio Falace, Matias Wagner, Moran Gal, Davide Mei, Valerio Conti, Tiziana Pisano, Davide Aprile, Maria Sabina Cerullo, Antonio De Fusco, Silvia Giovedì, Annette Seibt, Daniella Magen, Tilman Polster, Ayelet Eran, Sarah L Stenton, Chiara Fiorillo, Sarit Ravid, Ertan Mayatepek, Hava Hafner, Saskia Wortmann, Erez Y Levanon, Carla Marini, Hanna Mandel, Fabio Benfenati, Felix Distelmaier, Anna Fassio, and Renzo Guerrini. Biallelic dmxl2 mutations impair autophagy and cause ohtahara syndrome with progressive course. Brain : a journal of neurology, 142:3876-3891, Dec 2019. URL: https://doi.org/10.1093/brain/awz326, doi:10.1093/brain/awz326. This article has 51 citations.

  4. (OpenTargets Search: -DMXL2): Open Targets Query (-DMXL2, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  5. (esposito2019biallelicdmxl2mutations pages 13-14): Alessandro Esposito, Antonio Falace, Matias Wagner, Moran Gal, Davide Mei, Valerio Conti, Tiziana Pisano, Davide Aprile, Maria Sabina Cerullo, Antonio De Fusco, Silvia Giovedì, Annette Seibt, Daniella Magen, Tilman Polster, Ayelet Eran, Sarah L Stenton, Chiara Fiorillo, Sarit Ravid, Ertan Mayatepek, Hava Hafner, Saskia Wortmann, Erez Y Levanon, Carla Marini, Hanna Mandel, Fabio Benfenati, Felix Distelmaier, Anna Fassio, and Renzo Guerrini. Biallelic dmxl2 mutations impair autophagy and cause ohtahara syndrome with progressive course. Brain : a journal of neurology, 142:3876-3891, Dec 2019. URL: https://doi.org/10.1093/brain/awz326, doi:10.1093/brain/awz326. This article has 51 citations.

  6. (esposito2019biallelicdmxl2mutations pages 8-10): Alessandro Esposito, Antonio Falace, Matias Wagner, Moran Gal, Davide Mei, Valerio Conti, Tiziana Pisano, Davide Aprile, Maria Sabina Cerullo, Antonio De Fusco, Silvia Giovedì, Annette Seibt, Daniella Magen, Tilman Polster, Ayelet Eran, Sarah L Stenton, Chiara Fiorillo, Sarit Ravid, Ertan Mayatepek, Hava Hafner, Saskia Wortmann, Erez Y Levanon, Carla Marini, Hanna Mandel, Fabio Benfenati, Felix Distelmaier, Anna Fassio, and Renzo Guerrini. Biallelic dmxl2 mutations impair autophagy and cause ohtahara syndrome with progressive course. Brain : a journal of neurology, 142:3876-3891, Dec 2019. URL: https://doi.org/10.1093/brain/awz326, doi:10.1093/brain/awz326. This article has 51 citations.

  7. (esposito2019biallelicdmxl2mutations pages 10-11): Alessandro Esposito, Antonio Falace, Matias Wagner, Moran Gal, Davide Mei, Valerio Conti, Tiziana Pisano, Davide Aprile, Maria Sabina Cerullo, Antonio De Fusco, Silvia Giovedì, Annette Seibt, Daniella Magen, Tilman Polster, Ayelet Eran, Sarah L Stenton, Chiara Fiorillo, Sarit Ravid, Ertan Mayatepek, Hava Hafner, Saskia Wortmann, Erez Y Levanon, Carla Marini, Hanna Mandel, Fabio Benfenati, Felix Distelmaier, Anna Fassio, and Renzo Guerrini. Biallelic dmxl2 mutations impair autophagy and cause ohtahara syndrome with progressive course. Brain : a journal of neurology, 142:3876-3891, Dec 2019. URL: https://doi.org/10.1093/brain/awz326, doi:10.1093/brain/awz326. This article has 51 citations.

  8. (falace2024vatpasedysfunctionin pages 8-9): Antonio Falace, Greta Volpedo, Marcello Scala, Federico Zara, Pasquale Striano, and Anna Fassio. V-atpase dysfunction in the brain: genetic insights and therapeutic opportunities. Cells, 13:1441, Aug 2024. URL: https://doi.org/10.3390/cells13171441, doi:10.3390/cells13171441. This article has 27 citations.

  9. (esposito2019biallelicdmxl2mutations pages 11-12): Alessandro Esposito, Antonio Falace, Matias Wagner, Moran Gal, Davide Mei, Valerio Conti, Tiziana Pisano, Davide Aprile, Maria Sabina Cerullo, Antonio De Fusco, Silvia Giovedì, Annette Seibt, Daniella Magen, Tilman Polster, Ayelet Eran, Sarah L Stenton, Chiara Fiorillo, Sarit Ravid, Ertan Mayatepek, Hava Hafner, Saskia Wortmann, Erez Y Levanon, Carla Marini, Hanna Mandel, Fabio Benfenati, Felix Distelmaier, Anna Fassio, and Renzo Guerrini. Biallelic dmxl2 mutations impair autophagy and cause ohtahara syndrome with progressive course. Brain : a journal of neurology, 142:3876-3891, Dec 2019. URL: https://doi.org/10.1093/brain/awz326, doi:10.1093/brain/awz326. This article has 51 citations.

  10. (guerrini2023developmentalandepileptic pages 3-4): Renzo Guerrini, Valerio Conti, Massimo Mantegazza, Simona Balestrini, Aristea S. Galanopoulou, and Fabio Benfenati. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiological Reviews, 103:433-513, Jan 2023. URL: https://doi.org/10.1152/physrev.00063.2021, doi:10.1152/physrev.00063.2021. This article has 216 citations and is from a highest quality peer-reviewed journal.

  11. (grew2024yieldandutility pages 1-2): Emily C Grew, Mayuri Reddy, Hayley Reichner, Jinsoo Kim, Misbah Salam, and Anjum Hashim. Yield and utility of routine epilepsy panel genetic testing among young patients with seizures. Journal of Child Neurology, 39:138-146, Mar 2024. URL: https://doi.org/10.1177/08830738241240516, doi:10.1177/08830738241240516. This article has 1 citations and is from a peer-reviewed journal.

  12. (esposito2019biallelicdmxl2mutations pages 2-3): Alessandro Esposito, Antonio Falace, Matias Wagner, Moran Gal, Davide Mei, Valerio Conti, Tiziana Pisano, Davide Aprile, Maria Sabina Cerullo, Antonio De Fusco, Silvia Giovedì, Annette Seibt, Daniella Magen, Tilman Polster, Ayelet Eran, Sarah L Stenton, Chiara Fiorillo, Sarit Ravid, Ertan Mayatepek, Hava Hafner, Saskia Wortmann, Erez Y Levanon, Carla Marini, Hanna Mandel, Fabio Benfenati, Felix Distelmaier, Anna Fassio, and Renzo Guerrini. Biallelic dmxl2 mutations impair autophagy and cause ohtahara syndrome with progressive course. Brain : a journal of neurology, 142:3876-3891, Dec 2019. URL: https://doi.org/10.1093/brain/awz326, doi:10.1093/brain/awz326. This article has 51 citations.

  13. (majethia2024geneticandphenotypic pages 1-3): Purvi Majethia, Namanpreet Kaur, Selinda Mascarenhas, Lakshmi Priya Rao, Shruti Pande, Dhanya Lakshmi Narayanan, Vivekananda Bhat, Shalini S. Nayak, Karthik Vijay Nair, Adarsh Pooradan Prasannakumar, Ankur Chaurasia, Bhagesh Hunakunti, Nalesh Jadhav, Sheeba Farooqui, Mayuri Yeole, Vishaka Kothiwale, Rohit Naik, Veena Bhat, Shrikiran Aroor, Leslie Lewis, Jayashree Purkayastha, Y. Ramesh Bhat, B. K. Praveen, B. L. Yatheesha, Siddaramappa J. Patil, Sheela Nampoothiri, Nutan Kamath, Shahyan Siddiqui, Stephanie Bielas, Katta Mohan Girisha, Suvasini Sharma, and Anju Shukla. Genetic and phenotypic landscape of pediatric-onset epilepsy in 142 indian families: counseling and therapeutic implications. Clinical genetics, 105:639-654, Feb 2024. URL: https://doi.org/10.1111/cge.14495, doi:10.1111/cge.14495. This article has 8 citations and is from a peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 5
Resolved 5
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 5
On topic 3
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 47
Resolved 47
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0

Every term resolved, and every label the report gave matched.